<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69454</article-id><article-id pub-id-type="doi">10.7554/eLife.69454</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-234958"><name><surname>Liu</surname><given-names>Qiaoling</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-234959"><name><surname>Xiao</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-240457"><name><surname>Sun</surname><given-names>Zhen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-240458"><name><surname>Wang</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-234960"><name><surname>Wang</surname><given-names>Lina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-234961"><name><surname>Wang</surname><given-names>Na</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-234962"><name><surname>Wang</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-234963"><name><surname>Song</surname><given-names>Chengli</given-names></name><email>chenglisong2015@hotmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-221136"><name><surname>Yang</surname><given-names>Qingkai</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6628-5393</contrib-id><email>yangqingkai@dmu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Institute of Cancer Stem Cell, DaLian Medical University</institution><addr-line><named-content content-type="city">Dalian</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Department of General Surgery, Second Affiliated Hospital, DaLian Medical University</institution><addr-line><named-content content-type="city">Dalian</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution>Shengjing Hospital of China Medical University</institution><country>China</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>23</day><month>06</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e69454</elocation-id><history><date date-type="received" iso-8601-date="2021-04-15"><day>15</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-06-21"><day>21</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Liu et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Liu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-69454-v2.pdf"/><abstract><p>Targeting DNA repair pathway offers an important therapeutic strategy for <italic>Homo sapiens</italic> (human) cancers. However, the failure of DNA repair inhibitors to markedly benefit patients necessitates the development of new strategies. Here, we show that exosome component 1 (EXOSC1) promotes DNA damages and sensitizes human kidney renal clear cell carcinoma (KIRC) cells to DNA repair inhibitor. Considering that endogenous source of mutation (ESM) constantly assaults genomic DNA and likely sensitizes human cancer cells to the inhibitor, we first analyzed the statistical relationship between the expression of individual genes and the mutations for KIRC. Among the candidates, EXOSC1 most notably promoted DNA damages and subsequent mutations via preferentially cleaving C site(s) in single-stranded DNA. Consistently, EXOSC1 was more significantly correlated with C&gt;A transversions in coding strands than these in template strands in human KIRC. Notably, KIRC patients with high EXOSC1 showed a poor prognosis, and EXOSC1 sensitized human cancer cells to poly(ADP-ribose) polymerase inhibitors. These results show that EXOSC1 acts as an ESM in KIRC, and targeting EXOSC1 might be a potential therapeutic strategy.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer</kwd><kwd>cell biology</kwd><kwd>inhibitor</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81872310</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Qingkai</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82073123</award-id><principal-award-recipient><name><surname>Song</surname><given-names>Chengli</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2020M680956</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Lina</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>EXOSC1 acts as an endogenous source of mutation inkidney renalclear cell carcinoma via cleaving single-stranded DNA.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>DNA damages and subsequent mutations are central to development, progression, and treatment of nearly all cancers (<xref ref-type="bibr" rid="bib5">Brown et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">Farmer et al., 2005</xref>; <xref ref-type="bibr" rid="bib19">Jeggo et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Pearl et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Roos et al., 2016</xref>). Cancer cells frequently decrease DNA repair pathways and increase endogenous sources of mutation (ESM) to drive mutations (<xref ref-type="bibr" rid="bib5">Brown et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">Farmer et al., 2005</xref>; <xref ref-type="bibr" rid="bib19">Jeggo et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Pearl et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Roos et al., 2016</xref>). Hence, cancer cells are often more reliant on a subset of DNA repair pathway(s) to survive DNA damages. Targeting critical DNA repair members, such as poly (ADP-ribose) polymerases (PARPs) (<xref ref-type="bibr" rid="bib5">Brown et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Tubbs and Nussenzweig, 2017</xref>), offers a therapeutic strategy for cancers (<xref ref-type="bibr" rid="bib46">Tutt et al., 2010</xref>). Inhibition of PARPs by small-molecule compounds disrupts the ability of cancer cells to survive ongoing DNA damage and results in cell cycle arrest and/or cell death (<xref ref-type="bibr" rid="bib26">Lord and Ashworth, 2012</xref>). However, the failure of PARP inhibitors (PARPis) to markedly benefit patients suggests the necessity for developing new strategies. Due to the central role of ESM in ongoing DNA damages, there is a need for the identification and understanding of ESM.</p><p>ESM constantly assaults genomic DNA and almost inevitably leads to mutations (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib19">Jeggo et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Roos et al., 2016</xref>). However, most of the ESM studies were focused on deamination. The significance of deamination as an ESM is supported mainly by two observations: (1) Transitions show higher frequency than expected by chance, although there are twice as many possible transversions. Nucleotide substitutions consist of two types: transition and transversion (<xref ref-type="bibr" rid="bib1">Alexandrov et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">Burgess, 2019</xref>; <xref ref-type="bibr" rid="bib36">Petljak et al., 2019</xref>). Transition is a substitution in which one base is replaced by another of the same class (purine or pyrimidine), while transversion is a substitution in which a purine is replaced with a pyrimidine or vice versa (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). (2) C&gt;T transitions at methylated cytosine in CG base pairs display a higher frequency than expected (<xref ref-type="bibr" rid="bib1">Alexandrov et al., 2013</xref>; <xref ref-type="bibr" rid="bib1">Alexandrov et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">Burgess, 2019</xref>; <xref ref-type="bibr" rid="bib17">Hutchinson, 2013</xref>; <xref ref-type="bibr" rid="bib36">Petljak et al., 2019</xref>). Therefore, activation-induced cytidine deaminase (AID) (<xref ref-type="bibr" rid="bib2">Barlow et al., 2013</xref>; <xref ref-type="bibr" rid="bib15">Greaves, 2018</xref>; <xref ref-type="bibr" rid="bib35">Petersen-Mahrt et al., 2002</xref>) and apolipoprotein B mRNA editing enzyme catalytic (APOBEC) family (<xref ref-type="bibr" rid="bib1">Alexandrov et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Buisson et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Hutchinson, 2013</xref>; <xref ref-type="bibr" rid="bib30">McGranahan et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Robertson et al., 2017</xref>) catalyzing the deamination of C were identified as ESMs. Unfortunately, some cancers, such as kidney renal clear cell carcinoma (KIRC), show the low mutation proportion at CG base pairs and low APOBEC expression (<xref ref-type="bibr" rid="bib9">Burns et al., 2013b</xref>), raising the potential roles of unidentified ESMs.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Identification of candidate ESMs in KIRC by statistical analyses.</title><p>(<bold>A</bold>) Schematic of this study. (<bold>B</bold>) Illustration of base substitutions. (<bold>C</bold>) Schematic showing the archaeal and eukaryotic exosome complexes viewed from the top. (<bold>D</bold>) Summary statistics for the six types of c-substitutions in KIRC. (<bold>E</bold>) Scatter plots showing the correlation between the rank of mutation and gene expression. Each plot represents one KIRC sample. The orange dashed line shows the best fit for visualization. P values were calculated by Spearman’s rank correlation. (<bold>F</bold>) Volcano plots of p and r values calculated by Spearman's correlation analyses. Each plot represents one gene. The top 1% of genes were taken as candidates and marked in red. (<bold>G</bold>) Box plots showing ASNS expression in the high and low C&gt;A/G&gt;T mutation groups. The expression was normalized to TBP. (<bold>H</bold>) Volcano plots showing the p and fold change (FC) values calculated by the two-tailed Student’s <italic>t</italic>-test. Each plot represents one gene. FC was calculated by the formula: FC=the mean gene expression in the high group/that in the low group. The top 1% of genes were taken as candidates and marked in red. (<bold>I</bold>) C-substitution mutation frequencies in five types of major cancers. (<bold>J, K</bold>) Mutation spectra of the TP53 gene in BRCA (<bold>J</bold>) and VHL gene in KIRC (<bold>L</bold>). (<bold>L</bold>) Kaplan-Meier (KM) analyses of OS between VHL C&gt;A/G&gt;T and C&gt;T/G&gt;A mutation groups. The median OSs in the C&gt;A/G&gt;T and C&gt;T/G&gt;A groups were 72.95 and 108.91 months, respectively. The p value was obtained from the log-rank test. (<bold>M</bold>) Venn diagram showing the overlap of the candidate genes identified by three types of statistical analyses as noted. ESM, endogenous source of mutation; KIRC, kidney renal clear cell carcinoma; OS, overall survival.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Identification of candidate ESMs in KIRC by statistical analyses.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Identification of candidate ESMs in KIRC by statistical analyses.</title><p>(<bold>A</bold>) The top-ranked 200 genes of each c-substitution type (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) were applied for Gene Ontology (GO) enrichment analyses by Metascape (<ext-link ext-link-type="uri" xlink:href="https://metascape.org/gp/index.html#/main/step1">metascape.org</ext-link>). (<bold>B</bold>) Summary statistics for the information of function-related mutations in KIRC. (<bold>C, D</bold>) Mutation spectra of TP53 (<bold>C</bold>) and VHL (<bold>D</bold>) normalized by the nucleotide abundance. ESM, endogenous source of mutation.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Identification of candidate ESMs in KIRC by statistical analyses.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Due to advances in sequencing technology and the great efforts of The Cancer Genome Atlas (TCGA), it is now possible to explore the statistical relationship between mutations and the expression of individual genes in multiple cancer types (<xref ref-type="bibr" rid="bib51">Weinstein et al., 2013</xref>). The majority of patients included in the TCGA database are accompanied by data regarding both mutations and genome-wide expression of individual genes (<xref ref-type="bibr" rid="bib51">Weinstein et al., 2013</xref>). Because that DNA damages often comprise a major source of mutation, the relativity between DNA damage and mutation allows quantitative analyses of mutation to be taken as a proxy of DNA damage (<xref ref-type="bibr" rid="bib5">Brown et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Jeggo et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Pearl et al., 2015</xref>). Furthermore, the gene-specific correlation between mRNA and protein levels allows quantitative analyses of individual gene expression as an indicator for the corresponding protein (<xref ref-type="bibr" rid="bib34">Peng et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Uhlen et al., 2017</xref>; <xref ref-type="bibr" rid="bib53">Zhang et al., 2017</xref>). Hence, analyses of the cancer cohort may identify candidate ESMs (<xref ref-type="bibr" rid="bib45">Tubbs and Nussenzweig, 2017</xref>).</p><p>The exosome is an evolutionarily conserved multiprotein complex formed by exosome components (EXOSCs) (<xref ref-type="bibr" rid="bib3">Bousquet-Antonelli et al., 2000</xref>; <xref ref-type="bibr" rid="bib4">Brown et al., 2000</xref>; <xref ref-type="bibr" rid="bib44">Tomecki et al., 2010</xref>). In eukaryotes, the exosome complex has a ‘ring complex’ (EXOSC4–EXOSC9) and a ‘cap’ structure (EXOSC1–EXOSC3) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The human exosome complex may also contain two additional subunits, EXOSC10 and EXOSC11 (<xref ref-type="bibr" rid="bib16">Houseley et al., 2006</xref>; <xref ref-type="bibr" rid="bib28">Lorentzen et al., 2008</xref>; <xref ref-type="bibr" rid="bib24">Liu et al., 2006</xref>; <xref ref-type="bibr" rid="bib50">Wasmuth et al., 2014</xref>), which provide 3′–5′ exo- and/or endoribonuclease activities (<xref ref-type="bibr" rid="bib18">Januszyk and Lima, 2014</xref>; <xref ref-type="bibr" rid="bib21">Kilchert et al., 2016</xref>). The exosome is well known to degrade RNA (<xref ref-type="bibr" rid="bib18">Januszyk and Lima, 2014</xref>; <xref ref-type="bibr" rid="bib21">Kilchert et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Ulmke et al., 2021</xref>). Hence, the exosome was reported to protect cells from genomic instability via degrading the DNA/RNA hybrids and restricting DNA strand mutational asymmetry (<xref ref-type="bibr" rid="bib23">Lim et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Pefanis and Basu, 2015</xref>; <xref ref-type="bibr" rid="bib32">Pefanis et al., 2015</xref>). Interestingly, the cap unit EXOSC2 is stably associated with the exosome complex, while EXOSC1 is not stably associated (<xref ref-type="bibr" rid="bib12">Dai et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Malet et al., 2010</xref>), suggesting that EXOSC1 might be involved in some functions independent of the complex.</p><p>In this study, we show that EXOSC1 acts as an ESM and sensitizes cancer cells to PARPi in KIRC. Due to the role of exosome in maintaining genomic stability, these results also indicate that a unit of multiprotein complex can play a role opposite to that of the complex.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Identification of candidate ESMs in KIRC</title><p>Because that ESMs constantly assault genomic DNA, we hypothesized that ESMs likely sensitized cancer cells to the inhibitors of DNA repair pathways. Considering that substitution is the most abundant mutation in all cancers, we initiated this study to identify the candidate ESMs responsible for substitution mutations. To identify the candidate ESMs other than deamination, we focused on KIRC for three reasons: (1) KIRC shows the lowest proportion of mutations at CG in major cancer types (<xref ref-type="bibr" rid="bib9">Burns et al., 2013b</xref>), suggesting that the deamination contributes less to the mutations in KIRC. (2) Only low expressions of AID and APOBECs were detected in KIRC (<xref ref-type="bibr" rid="bib9">Burns et al., 2013b</xref>). (3) The kidney potentially suffers less from exogenous source of mutations (EOSMs) (<xref ref-type="bibr" rid="bib25">Loeb, 2011</xref>; <xref ref-type="bibr" rid="bib37">Roberts and Gordenin, 2014</xref>). RNA-seq and exomic mutation data corresponding to 532 KIRC patients and 30,254 somatic substitution mutations in the TCGA were retrieved from The cBio Cancer Genomics Portal (<ext-link ext-link-type="uri" xlink:href="http://cbioportal.org">http://cbioportal.org</ext-link>) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Because that ESMs likely show a similar impact on the template and code DNA strands, the 12 types of substitution were groups into six types of complementary substitution (c-substitution) to simplify the analyses (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><p>Spearman’s rank analysis was first performed to assess the correlation between each c-substitution type and the genome-wide expression of individual genes. Resultant p and r values were used for the further analyses. For example, GAPDH showed a p=0.0011 and r=0.16 correlation with C&gt;A/G&gt;T c-substitution, indicating that GAPDH expression displayed a positive correlation with C&gt;A/G&gt;T (<xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Similarly, CRB3 was also positively correlated with C&gt;A/G&gt;T (<xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Although the p values of multiple genes were lower than 0.05 (<xref ref-type="fig" rid="fig1">Figure 1F</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), only top-ranked 200 genes (approximately 1% of the genome-wide genes) were taken as the candidates for each c-substitution type (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Gene Ontology (GO) enrichment analyses indicated that, generally, these top candidate genes showed the enrichment in ‘mitochondrial gene expression’ and ‘organophosphate biosynthetic process’ (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref> and <xref ref-type="supplementary-material" rid="fig1s1sdata1">Figure 1—figure supplement 1—source data 1</xref>).</p><p>Student’s <italic>t</italic>-test analysis was then used to determine whether the expression difference of individual genes between the high and low c-substitution groups is significant. The expression of individual genes in each patient was normalized by a housekeeping gene, TATA-binding protein (TBP), as previously described (<xref ref-type="bibr" rid="bib8">Burns et al., 2013a</xref>; <xref ref-type="bibr" rid="bib9">Burns et al., 2013b</xref>). According to each c-substitution, 532 KIRC patients were grouped into three groups (high, medium, and low). The difference of individual genes between the high and low c-substitution mutation groups was then analyzed by Student’s <italic>t</italic>-test. Resultant p and fold change (FC) values were used forfurther analyses. For example, ASNS with p=0.0005 and FC=1.39 indicates that ASNS was increased in the high group (<xref ref-type="fig" rid="fig1">Figure 1G</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Although the p values of multiple genes were lower than 0.05 (<xref ref-type="fig" rid="fig1">Figure 1H</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), only the top 200 genes with high FC and p&lt;0.05 were taken as the candidates (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Notably, none of the APOBEC family members were identified as candidate by correlation or Student’s <italic>t</italic>-test analyses, supporting that deamination contributes less to the mutations in KIRC.</p><p>Next, we performed meta-analyses to determine which of the six c-substitution types to focus on. Mutation frequencies of c-substitution types were first analyzed in five major cancers: breast adenocarcinoma (BRCA), glioblastoma multiforme (GBM), bladder urothelial carcinoma (BLCA), acute myeloid leukemia (AML), and KIRC, which potentially suffer less from the EOSMs. Although most frequently mutated substitutions in the five major cancers were C&gt;T/G&gt;A, KIRC displayed higher frequencies of C&gt;A/G&gt;T, A&gt;T/T&gt;A, and A&gt;C/ &gt;G mutations than the other four cancers did (<xref ref-type="fig" rid="fig1">Figure 1I</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Among the KIRC patient mutations, most c-substitutions are function-related (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Notably, the transversions in KIRC showed more capacities to result in function-related mutations than transitions (C&gt;T/G&gt;A and A&gt;G/T&gt;C) did (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Using tumor protein p53 (TP53) as control, we then assessed the frequencies of c-substitution types in von Hippel-Lindau tumor suppressor (VHL), the most frequently mutated gene in KIRC. Consistent with previous studies (<xref ref-type="bibr" rid="bib8">Burns et al., 2013a</xref>; <xref ref-type="bibr" rid="bib20">Kandoth et al., 2013</xref>), the most frequent c-substitution type of TP53 mutations in BRCA was C&gt;T/G&gt;A (<xref ref-type="fig" rid="fig1">Figure 1J</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), while the most frequent type of VHL mutations in KIRC was C&gt;A/G&gt;T (p=0.004, chi-squared test) (<xref ref-type="fig" rid="fig1">Figure 1K</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Even after normalization according to the base frequency, this phenomenon was still observed (p=0.021) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C and D</xref>, and <xref ref-type="supplementary-material" rid="fig1s1sdata1">Figure 1—figure supplement 1—source data 1</xref>). Further, Kaplan–Meier (KM) analysis of overall survival (OS) indicated that patients with VHL C&gt;A/G&gt;T mutations showed poor OS (<xref ref-type="fig" rid="fig1">Figure 1L</xref>). These observations raised the significance of C&gt;A/G&gt;T c-substitutions in KIRC.</p><p>We then evaluated the expression difference of individual genes between the VHL C&gt;A/G&gt;T mutation-positive and mutation-negative patients. Student’s <italic>t</italic>-tests analyses showed that 36 genes displayed p&lt;0.05 (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Further overlap analyses demonstrated that cyclin B1 (CCNB1), exosome component 1 (EXOSC1), and RAB5 interacting factor (RAB5IF) were identified as candidate ESMs for C&gt;A/G&gt;T by all of the above analyses (<xref ref-type="fig" rid="fig1">Figure 1M</xref>).</p></sec><sec id="s2-2"><title>EXOSC1 promotes mutations in <italic>Escherichia coli</italic></title><p>To evaluate the capability of the candidate gene to promote mutation, rifampicin-resistant assay in <italic>Escherichia coli</italic> was performed as previously described (<xref ref-type="bibr" rid="bib35">Petersen-Mahrt et al., 2002</xref>). Because that mutation of the rifampicin-targeted rpoB gene to rifampicin resistance (Rif<sup>R</sup>) occurs at a low frequency, the capability of a gene to mutate rpoB to Rif<sup>R</sup> can be evaluated by fluctuation analysis (<xref ref-type="bibr" rid="bib35">Petersen-Mahrt et al., 2002</xref>). Therefore, AID, an known ESM (<xref ref-type="bibr" rid="bib35">Petersen-Mahrt et al., 2002</xref>), was used as a positive control. Four genes (CDK5, TARBP2, PSAT1, and NECAB3) were used as random controls (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref> and <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). These genes were expressed in <italic>E. coli</italic> under the regulation of a trp/lac (tac) hybrid promoter, which could be activated by isopropyl β-D-1-thiogalactopyranoside (IPTG) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Consistent with a previous study (<xref ref-type="bibr" rid="bib35">Petersen-Mahrt et al., 2002</xref>), AID enhanced mutation in <italic>E. coli</italic> (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). Notably, EXOSC1 more significantly increased mutations than AID did (p=4.08 × 10<sup>−5</sup>) (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). We then evaluated the capabilities of EXOSC1 homologs (EXOSC2–EXOSC9) to promote mutations (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Among the members of exosome complex, EXOSC1 most notably enhanced mutation in <italic>E. coli</italic> (p=3.5 × 10<sup>−11</sup>) (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). To determine whether the increase in mutation frequency stemmed from EXOSC1 protein itself, rifampicin-resistant assays were performed in the presence or absence of IPTG, the transcriptional inducer. As shown in <xref ref-type="fig" rid="fig2">Figure 2E–F</xref>, IPTG absence notably decreased the mutation frequency (p=1.29 × 10<sup>−9</sup>), indicating that the protein of EXOSC1 promoted the mutation. Additionally, we evaluated the impact of EXOSC1 on the growth of <italic>E. coli</italic>. As shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>, EXOSC1 expression only slightly decreased cell growth, which might be due to the increase in mutation burden (<xref ref-type="bibr" rid="bib41">Schaaper and Dunn, 1987</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>EXOSC1 promotes mutations in <italic>Escherichia coli.</italic></title><p>(<bold>A</bold>) Western blot showing His-tagged protein levels in <italic>E. coli</italic>. (<bold>B, C</bold>) The frequencies of the Rif<sup>R</sup> mutation in the <italic>E. coli</italic> cells expressing candidate ESMs (<bold>B</bold>) or exosome family members (<bold>C</bold>). The vector and AID were used as negative and positive controls, respectively. Each plot represents the mutational frequency of an independent overnight culture (n=30). Median mutational frequency of the gene is noted. (<bold>D</bold>) Frequencies of the Rif<sup>R</sup> mutation in the <italic>E. coli</italic> cells treated with and without IPTG (n=30). (<bold>E, F</bold>) Representative images of <italic>E. coli</italic> cells treated with (<bold>E</bold>) and without (<bold>F</bold>) IPTG. (<bold>G</bold>) The mutational distribution in 25 independent Rif<sup>R</sup> colonies transformed by vector or EXOSC1. (<bold>H, I</bold>) Summary of the c-substitutions in Rif<sup>R</sup> colonies transformed by vector (<bold>H</bold>) and EXOSC1 (<bold>I</bold>). (<bold>J</bold>) The mutational frequencies of each c-substitution in Rif<sup>R</sup> colonies. The p value was calculated by Fisher's exact test.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>EXOSC1 promotes mutations in <italic>E. coli</italic>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>EXOSC1 promotes mutations in <italic>Escherichia coli.</italic></title><p>(<bold>A</bold>) Setup plot showing the overlap numbers of the candidate genes of the six types of c-substitutions. More details can be found in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>. (<bold>B</bold>) Western blot showing the His-tagged protein levels of the exosome complex members in the <italic>E. coli</italic> cells. (<bold>C</bold>) Growth rates of control and EXOSC1-transformed cells in the presence of IPTG (n=5). (<bold>D</bold>) Frequencies of c-substitutions in Rif<sup>R</sup> colonies were normalized to the nucleotide abundances. The p value was calculated by Fisher's exact test.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>EXOSC1 promotes mutations in <italic>E. coli</italic>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig2-figsupp1-v2.tif"/></fig></fig-group><p>Next, the mutation spectra of Rif<sup>R</sup> were analyzed by sequencing the rpoB gene PCR products from rifampicin-resistant clones. Sequencing of rpoB gene in 25 randomly selected rifampicin-resistant clones indicated that most of mutations in control clones were C&gt;T/G&gt;A transitions, while EXOSC1 frequently promoted C&gt;A/G&gt;T transversion mutations (<xref ref-type="fig" rid="fig2">Figure 2G–I</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). Moreover, most of C&gt;A/G&gt;T transversions in EXOSC1-transformed cells were clustered at C1576 (10/36 mutations) and C1699 (6/36 mutations), whereas C&gt;T/G&gt;A transitions in control cells showed a distinct distribution with major hot spots at C1565 (6/32 mutations) and C1721 (5/32 mutations) (<xref ref-type="fig" rid="fig2">Figure 2G</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). Hence, it was suggested that the mutations in control and EXOSC1-transformed cells were promoted by a distinct mechanism. Interestingly, EXOSC1-transformed cells also showed a shift of C&gt;A/G&gt;T mutations from 6% (2/32 mutations) to 69% (25/36 mutations) (p=4.03 × 10<sup>−7</sup>, chi-squared test) (<xref ref-type="fig" rid="fig2">Figure 2H–J</xref>). Even after normalization to the base frequency, this phenomenon was still significant (p=1.47 × 10<sup>−6</sup>) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref> and <xref ref-type="supplementary-material" rid="fig2s1sdata1">Figure 2—figure supplement 1—source data 1</xref>).</p></sec><sec id="s2-3"><title>EXOSC1 cleaves single-stranded DNA</title><p>Considering that the exosome is well known to degrade RNA, we speculated that EXOSC1 might promote mutation through cleaving DNA. Therefore, EXOSC1 was expressed and purified in vitro (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The resultant EXOSC1 protein was incubated with generic single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), or the hybrid of DNA-RNA (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Polyacrylamide TBE-urea gel analyses of the resultant mixtures indicated that EXOSC1 notably cleaved ssDNA, while it displayed no detectable capability to cleave dsDNA or DNA-RNA hybrid (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>EXOSC1 cleaves ssDNA.</title><p>(<bold>A</bold>) Coomassie blue staining of in vitro purified EXOSC1 protein. (<bold>B</bold>) Schematic of synthetic DNA substrates. (<bold>C</bold>) In vitro cleavage assays of EXOSC1 using generic ssDNA, dsDNA, and DNA-RNA hybrid as substrates. The assays were performed in the presence of 1 μM oligonucleotides, 1 μM EXOSC1, 70 mM KCl, 700 μM MgCl<sub>2</sub>, 1 mM DTT, and 20 mM Tris–HCl pH 7.0. After incubation at 37°C for 4 hr, resultant samples were analyzed by 15% polyacrylamide TBE-urea gels. (<bold>D</bold>) Cleavage assays of EXOSC1 in the presence or absence of EXOSC3, EXOSC6, EXOSC7, and EXOSC8 using generic ssDNA as substrates. (<bold>E</bold>) Cleavage assays in the presence of the components as noted. (<bold>F</bold>) Cleavage assays of EXOSC1 at the pH as noted. (<bold>G</bold>) Time course cleavage assays of EXOSC1 using generic ssDNA as substrates. (<bold>H</bold>) Rate curve of EXOSC1 cleavage at 37°C and pH 7.0. dsDNA, double-stranded DNA; ssDNA, single-stranded DNA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>EXOSC1 cleaves ssDNA.</title><p>(<bold>A</bold>) In vitro cleavage assays of EXOSC1 homologs (EXOSC2–EXOSC9) using generic ssDNA, dsDNA, and DNA-RNA hybrid as substrates. (<bold>B</bold>) Cleavage assays of EXOSC1 in the presence/absence of EXOSC2, EXOSC4, EXOSC5, or EXOSC9. (<bold>C</bold>) Cleavage assays of exosome complex (EXOSC1–9) using generic ssDNA. dsDNA, double-stranded DNA; ssDNA, single-stranded DNA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig3-figsupp1-v2.tif"/></fig></fig-group><p>We then evaluated the capabilities of EXOSC1 homologs (EXOSC2–EXOSC9) to cleave ssDNA. The EXOSC protein was separately incubated with ssDNA. Gel analyses of the resultant mixtures indicated that, unlike EXOSC1, none of EXOSC2–EXOSC9 detectably cleaved ssDNA (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Considering that EXOSC1 is well known to form a complex with other exosome members, we also assessed the impact of the exosome members on the cleavage activity of EXOSC1. EXOSC1 was incubated with ssDNA in the presence of individual EXOSC1 homolog. Interestingly, EXOSC6, EXOSC7, and EXOSC8 decreased EXOSC1 cleavage activity (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), while EXOSC2, EXOSC3, EXOSC4, and EXOSC9 showed no detectable impact (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). And EXOSC1–9 (the exosome complex) displayed not detect DNA cleavage activity (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). We then evaluated the impact of the reaction components and pH on the cleavage activity of EXOSC1. It was found that K<sup>+</sup> and Mg<sup>2+</sup> enhanced the cleavage activity of EXOSC1 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), and EXOSC1 showed the highest cleavage activity at pH 7.0 (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Further analyses indicated that the cleavage rate of EXOSC1 was approximately 4 × 10<sup>−4</sup>/min at 37°C (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>).</p></sec><sec id="s2-4"><title>EXOSC1 prefers to cleave C sites in single-stranded DNA</title><p>Considering that the conserved exosome prefers to degrade the RNA with specific sequence (<xref ref-type="bibr" rid="bib11">Cvetkovic et al., 2017</xref>), we determined whether EXOSC1 preferred to cleave some site(s) in ssDNA. EXOSC1 was incubated with DNAs containing unbiased sequence and distinct 3′ end. Consistent with the result of the generic DNA, EXOSC1 cleaved unbiased ssDNA and displayed no detectable capability to cleave dsDNA or DNA-RNA hybrid (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). And only EXOSC1 displayed cleavage activity against unbiased ssDNA (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Interestingly, the cleavage rate against unbiased ssDNA (approximately 1.2 × 10<sup>−3</sup>/min) was higher than that against generic ssDNA (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), suggesting that the DNA sequence might show some impact on the activity of EXOSC1. Notably, mass spectrometry (MS) analyses (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C and D</xref>) demonstrated that the resultant mixtures contained more free C than the other three base types (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), suggesting that EXOSC1 preferred to cleave C sites in ssDNA. Consistently, EXOSC1 cleaved the ssDNA containing C&gt;A hot spot of VHL mutation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). Since EXOSC1 was correlated with the C&gt;A/G&gt;T c-substitution type, it was likely that EXOSC1 cleaved C sites in ssDNA and subsequently resulted in C&gt;A mutations through ‘A’ rule DNA repair.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>EXOSC1 prefers to cleave C sites in ssDNA.</title><p>(<bold>A, B</bold>) Cleavage assay of EXOSC1 using unbiased DNA, dsDNA, and DNA-RNA hybrid as substrates. (<bold>C, D</bold>) Cleavage assays of EXOSC1, EXOSC3, EXOSC7 and EXOSC8 using unbiased ssDNA as substrates. (<bold>E</bold>) Mass spectrometry (MS) analyses of the resultant mixtures described in (<bold>B</bold>). C, G, A, and T were detected by MS using nucleoside to base ion mass transitions of 228.1–112.2 (<bold>C</bold>), 268.1–152.1 (<bold>G</bold>), 252.2–136.1 (<bold>A</bold>), and 243.1–127.2 (<bold>T</bold>), respectively (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Standard curves were generated by a serial dilution of C, G, A, and T (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). Free C, G, A, and T contained in the reaction mixtures were quantified by standard curves. (<bold>F</bold>) Schematic showing that the consequence of C&gt;A mutation in the coding strand is distinct from that in the template strand. (<bold>G</bold>) Correlation between EXOSC1 expression and the c-substitution mutation as noted in KIRC. Each line represents one best fit for visualization. P values were from Spearman’s rank correlation. P and r values of C&gt;A mutations were 0.0001 and 0.19, respectively; C&gt;A/G&gt;T: p=0.0006, r=0.17; G&gt;T: p=0.0271, r=0.10; total mutations: p=0.0594, r=0.09; C/G&gt;G/C: p=0.5730, r=0.03. (<bold>H</bold>) Student’s <italic>t</italic>-test analyses of the expression difference of EXOSC1 between the high and low mutation groups. 2, 3, 4, and 5 represent the group numbers. For example, 4: the KIRC patients were grouped into four groups and the expression difference of EXOSC1 between the high and low mutation groups was analyzed by Student’s <italic>t</italic>-tests. FC = mean gene expression in the high group/that in the low group. dsDNA, double-stranded DNA; KIRC, kidney renal clear cell carcinoma; ssDNA, single-stranded DNA.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>EXOSC1 prefers to cleave C sites in ssDNA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>EXOSC1 prefers to cleave C sites in ssDNA.</title><p>(<bold>A</bold>) Cleavage assays of EXOSC2–EXOSC9 using unbiased ssDNA, dsDNA, and DNA-RNA hybrid as substrates. (<bold>B</bold>) Time course cleavage assays of EXOSC1 using unbiased ssDNA as substrates. (<bold>C</bold>) Base ion mass transitions for LC-MS/MS analyses of C, G, A, and T. Free nucleosides were detected using nucleoside to base ion mass transitions of 228.1–112.2 (<bold>C</bold>), 268.1–152.1 (<bold>G</bold>), 252.2–136.1 (<bold>A</bold>), and 243.1–127.2 (<bold>T</bold>). (<bold>D</bold>) LC-MS/MS standard curves of nucleoside as noted. (<bold>E</bold>) Cleavage assays of EXOSC1 using a 20 nt ssDNA containing hot spot of VHL mutation (186–205) as substrate. (<bold>F, G</bold>) Frequencies (<bold>F</bold>) and normalized frequencies (<bold>G</bold>) of 12 types of substitutions in Rif<sup>R</sup> colonies. P values were calculated by Fisher's exact test. (<bold>H</bold>) Correlation between EXOSC1 expression and the mutation as noted in KIRC. Each plot represents one KIRC sample. (<bold>I</bold>) Student’s <italic>t</italic>-test analyses of EXOSC1 expression difference between the high and low mutation groups. The 532 KIRC patients were grouped into two, three, four, or five groups to evaluate the impact of group number. (<bold>J, K</bold>) Summary statistics for the mutation as noted in KIRC. P values were calculated by the two-tailed Student’s <italic>t</italic>-test. dsDNA, double-stranded DNA; KIRC, kidney renal clear cell carcinoma; ssDNA, single-stranded DNA.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>EXOSC1 prefers to cleave C sites in ssDNA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig4-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig4-figsupp1-v2.tif"/></fig></fig-group><p>To evaluate the above hypothesis, we then determined whether EXOSC1-promoted mutations displayed strand asymmetries. Considering that EXOSC1 cleaved C sites in ssDNA but not DNA-RNA hybrid, we speculated that ‘transcribed’ temple strands likely bound by RNA were less cleaved by EXOSC1. As shown in <xref ref-type="fig" rid="fig4">Figure 4F</xref>, C&gt;A transversions in the ‘untranscribed’ coding strand lead to C&gt;A mutations in a gene, while C&gt;A transversions in the ‘transcribed’ template strand result in G&gt;T mutations. Therefore, the capability of EXOSC1 to promote strand mutational asymmetry can be evaluated by comparing C&gt;A and G&gt;T frequencies. We first analyzed the distributions of C&gt;A and G&gt;T substitutions, instead of the distributions of C&gt;A/G&gt;T c-substitution, in the EXOSC1-transformed <italic>E. coli</italic> cells described above. As shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F and G</xref>, C&gt;A substitution in rpoB gene was generated at a much higher frequency than G&gt;T. Compared with the control, EXOSC1 enhanced C&gt;A from 0% to 69% (p=2.67 × 10<sup>−7</sup>), while EXOSC1 only enhanced G&gt;T from 6% to 17% even without a significance (p=0.27) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F and G</xref>, and <xref ref-type="supplementary-material" rid="fig4s1sdata1">Figure 4—figure supplement 1—source data 1</xref>). Next, we evaluated C&gt;A strand asymmetry in KIRC using Spearman’s rank and Student’s <italic>t-</italic>test analyses. Spearman’s rank analyses indicated that EXOSC1 showed the highest correlation (r) with C&gt;A, and the correlation between EXOSC1 and G&gt;T was even lower than that between EXOSC1 and C&gt;A/G&gt;T (<xref ref-type="fig" rid="fig4">Figure 4G</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1H</xref>, and <xref ref-type="supplementary-material" rid="fig4s1sdata1">Figure 4—figure supplement 1—source data 1</xref>). To evaluate the impact of group number on the further Student’s <italic>t-</italic>test analyses, the KIRC patients were grouped into two, three, four, or five groups according to the mutation types C&gt;A, G&gt;T, C&gt;A/G&gt;T and total (12 substitution types). As expected, the EXOSC1 differences between the low and high C&gt;A/G&gt;T groups were more significant than those between the low and high groups of total (12 substitution types) mutations (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1I and J</xref>). Importantly, EXOSC1 showed more significant expression differences between the low and high C&gt;A groups than those between the low and high G&gt;T groups (<xref ref-type="fig" rid="fig4">Figure 4H</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1K</xref>), suggesting that EXOSC1 prefers to cleave C sites in ssDNA in vivo.</p></sec><sec id="s2-5"><title>EXOSC1 enhances DNA damage and mutations in KIRC cells</title><p>Considering that EXOSC1 cleaves DNA in vitro, we then evaluated the capability of EXOSC1 to promote intracellular DNA damage using γ-H2AX staining and neutral comet tail assays. The 769 P and TUHR14TKB KIRC cells were transfected with the plasmid encoding EXOSC1 using empty vector as a control (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). γ-H2AX staining analyses of the resultant cells demonstrated that EXOSC1 increased the γ-H2AX foci in the cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The number of γ-H2AX-positive cells was increased approximately sevenfold by EXOSC1 (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). While knockdown of EXOSC1 reduced the γ-H2AX foci (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B and C</xref>, and <xref ref-type="supplementary-material" rid="fig5s1sdata1">Figure 5—figure supplement 1—source data 1</xref>). Consistent with the results of γ-H2AX staining, comet tail analyses also indicated that EXOSC1 increased DNA damage (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>, and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>EXOSC1 enhances DNA damages and mutations in KIRC Cells.</title><p>(<bold>A</bold>) Representative fluorescent images of γ-H2AX foci in 769 P cells transfected with control (pCDH, empty vector) or pCDH-Flag EXOSC1 plasmids for 2 days. Scale bar=10 μm. (<bold>B</bold>) Percentage of cells with more than 20 γ-H2AX foci in the KIRC cells transfected with control or pCDH-Flag EXOSC1 plasmids for 2 days. (<bold>C</bold>) Percentage of cells with more than 20 γ-H2AX foci in the KIRC cells infected with lentivirus encoding shRNAi control (pLKO scramble) or pLKO sh-EXOSC1 for 2 days. (<bold>D</bold>) Representative images of DNA comets in 769 P cells transfected with control or pCDH-Flag EXOSC1 plasmids for 2 days. (<bold>E</bold>) Comet tail moment of the 769 P and TUHR14TKB cells transfected with control or pCDH-Flag EXOSC1 plasmids for 2 days. (<bold>F</bold>) 3D-PCR and subsequent sequencing analyses of the VHL mutations in the TUHR14TKB cells stably expressing control (vector) or EXOSC1 (pCDH-Flag EXOSC1, EXOSC1-OE). (<bold>G</bold>) 3D-PCR analyses of VHL in TUHR14TKB cells stably expressing control (pLKO.1 vector) or shRNA against EXOSC1 (pLKO shEXOSC1-1, EXOSC1-KD). (<bold>H</bold>) 3D-PCR analyses of VHL in TUHR14TKB cells stably expressing control, EXOSC1-OE and/or shRNA against XRCC1 (pMKO.1 shXRCC1-1, XRCC1-KD). (<bold>I</bold>) 3D-PCR analyses of VHL in TUHR14TKB cells stably expressing control (pLKO.1 vector), shRNA against EXOSC1 (pLKO shEXOSC1-1, EXOSC1-KD) and/or shRNA against XRCC1 (pMKO.1 shXRCC1-1, XRCC1-KD). (<bold>J</bold>) Schematic showing the subcutaneous xenograft tumor models. The 5 × 10<sup>6</sup> control, EXOSC1-OE and EXOSC1-KD 769 P cells were implanted subcutaneously. After 2 weeks, the resultant tumors were analyzed by 3D-PCR. (<bold>K</bold>) 3D-PCR analyses of VHL in the tumors described in (<bold>J</bold>). KIRC, kidney renal clear cell carcinoma.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>EXOSC1 enhances DNA damages and mutations in KIRC cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>EXOSC1 enhances DNA damages and mutations in KIRC cells.</title><p>(<bold>A</bold>) Western blot analyses of EXOSC1 in stable control, enhanced EXOSC1, and EXOSC1 knockdown cells. (<bold>B</bold>) Quantitative PCR analyses of EXOSC1 mRNA in the 769 P cells stably expressing shRNA (pLKO EXOSC1-1 or pLKO EXOSC1-2) against EXOSC1. (<bold>C</bold>) Representative fluorescence images of γ-H2AX foci in the 769 P cells stably expressing shRNA against control (empty vector) or EXOSC1 (pLKO EXOSC1-1, EXOSC1-KD). Scale bar=10 μm. (<bold>D, F</bold>) Western blot analyses of EXOSC1 and XRCC1 protein levels in the stable cells as noted. (<bold>E</bold>) Quantitative PCR analyses of the mRNA in the cells stably expressing shRNA against EXOSC1 and/or XRCC1. KIRC, kidney renal clear cell carcinoma.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>EXOSC1 enhances DNA damages and mutations in KIRC cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Due to the central role of DNA damage in mutations, we performed differential DNA denaturation PCR (3D-PCR) to determine whether EXOSC1 enhances mutation in KIRC cells. Because that DNA sequences with more A/T content can be amplified at lower denaturation temperatures than parental sequences, 3D-PCR enables qualitative estimates of genomic C/G&gt;A/T mutations in a population of cells. As shown in <xref ref-type="fig" rid="fig5">Figure 5F</xref>, the enhanced expression of EXOSC1 (EXOSC1-OE) increased the lower temperature amplicons (LTAs) of VHL, suggesting that EXOSC1 increased the mutations in VHL gene. Consistently, further sequencing analyses of the LTAs indicated that EXOSC1-OE cells showed more C&gt;A mutations in VHL gene (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p><p>Considering that the ‘A’ rule DNA repair is dependent on X-ray repair cross-complementing 1 (XRCC1) (<xref ref-type="bibr" rid="bib40">Sale et al., 2001</xref>), we knocked down XRCC1 to evaluate the role of XRCC1 in EXOSC1-promoted mutations (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D-F</xref>, and <xref ref-type="supplementary-material" rid="fig5s1sdata1">Figure 5—figure supplement 1—source data 1</xref>). 3D-PCR analyses of the resultant cells indicated that knockdown of XRCC1 impaired the capability of EXOSC1 to increase the LTAs (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Furthermore, both XRCC1 knockdown (XRCC1-KD) and EXOSC1 knockdown (EXOSC1-KD) decreased the LTAs (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>). Additionally, a subcutaneous xenograft tumor model was used to determine whether EXOSC1 enhances DNA mutations in vivo (<xref ref-type="fig" rid="fig5">Figure 5J</xref>). Stable control (vector), EXOSC1-OE, and EXOSC1-KD 769 P cells were subcutaneously implanted. After 2 weeks, 3D-PCR analyses of the resultant tumors indicated that EXOSC1 increased the LTAs of VHL, whereas knockdown of EXOSC1 reduced the LTAs (<xref ref-type="fig" rid="fig5">Figure 5K</xref>), suggesting that EXOSC1 enhanced mutations in KIRC.</p></sec><sec id="s2-6"><title>EXOSC1 sensitizes KIRC cells to PARP inhibitor</title><p>Considering the central roles of mutation in the process of cancers, we evaluated the potential clinical significance of EXOSC1 in KIRC using KM analyses. KM analyses of disease-free survival (DFS) and OS were performed using the clinical data from 532 KIRC patients in TCGA. The fragments per kilobase per million mapped reads (FPKMs) were used to evaluate the expression of EXOSC1 in KIRC (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>, and <xref ref-type="supplementary-material" rid="fig6s1sdata1">Figure 6—figure supplement 1—source data 1</xref>). The median-separation KM analyses indicated that high EXOSC1 group showed poor DFS and OS (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>, and <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). The median DFS in the low EXOSC1 group was 32.0 months longer than that in the high group (p=9.78 × 10<sup>−8</sup>, log-rank test) (<xref ref-type="fig" rid="fig6">Figure 6A</xref> and <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). Consistently, the median OS in the low EXOSC1 group was 36.9 months longer than that in the high group (p=2.2 × 10<sup>−8</sup>) (<xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). As expected, the best-separation KM analysis also indicated that high EXOSC1 group significantly showed poor OS (p=2.6 × 10<sup>−12</sup>) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>, and <xref ref-type="supplementary-material" rid="fig6s1sdata1">Figure 6—figure supplement 1—source data 1</xref>). Due to the critical role of VHL mutation in KIRC, we then evaluated the potential clinical significance of EXOSC1 in the presence and absence of VHL mutation. KM analyses indicated that high EXOSC1 group showed poor OS in both presence (median OS [high vs. low group]=65.2 vs. 98.5 months, p=0.015) and absence (median OS [high vs. low group]=75.7 vs. 104.5 months, p=1.0 × 10<sup>−5</sup>) of VHL mutation (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>, and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Furthermore, median separation KM analyses indicated that OS was not significantly different based on EXOC1 expression in BRCA, GBM, BLCA, and AML patients (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref> and <xref ref-type="supplementary-material" rid="fig6s1sdata1">Figure 6—figure supplement 1—source data 1</xref>), suggesting a role of EXOC1 in the treatment against KIRC.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>EXOSC1 sensitizes KIRC cells to PARP inhibitor.</title><p>(<bold>A, B</bold>) KM analyses of DFS (<bold>A</bold>) and OS (<bold>B</bold>) in KIRC patients with different EXOSC1 levels. P values were obtained from the log-rank test. (<bold>C</bold>) KM analysis of OS in KIRC patients with different EXOSC1 expression levels and VHL mutations. (<bold>D</bold>) Colony formation of control and EXOSC1-OE TUHR14TKB cells treated with 600 nM niraparib. (<bold>E, F</bold>) Clonogenic survival of control and EXOSC1-OE TUHR14TKB (<bold>E</bold>) and 769 P (<bold>F</bold>) cells treated with niraparib. (<bold>G, I</bold>) Tumor volumes of 769 P (<bold>G</bold>) and Caki-2 (<bold>I</bold>) xenografts treated with or without niraparib (n=4 groups; n=6 mice/group; ± SEM). (<bold>H, J</bold>) Body weight change percentage of 769 P (<bold>H</bold>) and Caki-2 (<bold>J</bold>) xenografts treated as described in (<bold>G</bold>). DFS, disease-free survival; KIRC, kidney renal clear cell carcinoma; KM, Kaplan-Meier; OS, overall survival.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>EXOSC1 sensitizes KIRC cells to PARP inhibitor.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>EXOSC1 sensitizes KIRC cells to PARP inhibitor.</title><p>(<bold>A</bold>) The fragments per kilobase per million mapped reads (FPKMs) of the noted gene in 532 KIRC patients. Each dot represents one KIRC patient. (<bold>B</bold>) Best separation KM analyses of OS in KIRC patients with different EXOSC1 levels. The median OS (low vs. high EXOSC1 group)=106.40 vs. 71.91 months. (<bold>C</bold>) Summary statistics for <xref ref-type="fig" rid="fig6">Figure 6C</xref>. (<bold>D</bold>) Median separation KM analyses of OS in the noted cancer patients with different EXOSC1 levels. (<bold>E</bold>) Clonogenic survival of control/EXOSC1-OE SNU-1272 and Caki-2 cells treated with niraparib. (<bold>F</bold>) Clonogenic survival of control/EXOSC1-OE KIRC cells treated with olaparib. KIRC, kidney renal clear cell carcinoma; KM, Kaplan-Meier; OS, overall survival.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>EXOSC1 sensitizes KIRC cells to PARP inhibitor.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-fig6-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69454-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Considering that EXOSC1 increases DNA damage, we speculated that EXOSC1 potentially sensitizes KIRC cells to the inhibitors of poly(ADP-ribose) polymerase (PARP), which treats cancers via blocking DNA repair. As previously described (<xref ref-type="bibr" rid="bib22">Li et al., 2020</xref>), colony formation assays were performed to evaluate the role of EXOSC1 in response to the PARP inhibitors, niraparib, and olaparib. Stable control (vector) and enhanced EXOSC1 (EXOSC1-OE) KIRC cells were seeded and treated with serial dilutions of PARP inhibitor until colonies were notably formed. As expected, both niraparib and olaparib more notably inhibited the KIRC cells with enhanced EXOSC1 (<xref ref-type="fig" rid="fig6">Figure 6D–F</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E and F</xref>, and <xref ref-type="supplementary-material" rid="fig6s1sdata1">Figure 6—figure supplement 1—source data 1</xref>), suggesting that EXOSC1 sensitized the cells to the PARP inhibitor. Next, we determined whether EXOSC1 could sensitize KIRC cells to niraparib in xenograft mouse models. The control and EXOSC1-OE cells were subcutaneously injected. Resultant tumor-bearing mice were grouped and treated by vehicle or niraparib. Consistent with the ex vivo results, niraparib more notably inhibited the tumor with enhanced EXOSC1 (<xref ref-type="fig" rid="fig6">Figure 6G and I</xref>, and <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>), indicating that EXOSC1 sensitized KIRC xenografts to the inhibitor. No significant weight loss was observed throughout the study, suggesting that the niraparib treatment was well tolerated (<xref ref-type="fig" rid="fig6">Figure 6H and J</xref>, and <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The genomic integrity of human cells is constantly assaulted by ESMs. Although human cells possess multi DNA repair mechanisms to counteract these constant assaults, not all lesions are correctly repaired and almost inevitably result in mutations. The central roles of these acquired mutations in nearly all cancers (<xref ref-type="bibr" rid="bib19">Jeggo et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Roos et al., 2016</xref>) emphasize the identification and understanding of the ESMs. Here, we show that EXOSC1 cleaves ssDNA and acts as an ESM in KIRC. Consistent with the capability of EXOSC1 to promote DNA damage and mutations, KIRC patients with high EXOSC1 showed a poor prognosis, and EXOSC1 also sensitized cancer cells to the PARP inhibitor.</p><p>Our results show that a unit of multiprotein complex can play a role distinct from the function(s) of the complex. Biological processes frequently require fine control over the formation of a multiprotein complex in a particular region of the cell. The exosome complex is well known for its roles in RNA degradation (<xref ref-type="bibr" rid="bib18">Januszyk and Lima, 2014</xref>; <xref ref-type="bibr" rid="bib21">Kilchert et al., 2016</xref>). However, the role of exosome complex members other than RNA binding and degradation remains elusive. Interestingly, EXOSC1 can disassociate from the exosome complex (<xref ref-type="bibr" rid="bib12">Dai et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Malet et al., 2010</xref>), suggesting that EXOSC1 might be involved in some functions independent of the exosome. Our study demonstrated that EXOSC1 acts as an ESM to promote mutagenesis. Conversely, previous studies have described that the exosome, as a multiprotein complex, protects cells from genomic instability by preventing the formation of DNA/RNA hybrids and restricting DNA strand mutational asymmetry (<xref ref-type="bibr" rid="bib23">Lim et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Pefanis and Basu, 2015</xref>; <xref ref-type="bibr" rid="bib32">Pefanis et al., 2015</xref>). This phenomenon can at least partially be explained by the finding that some exosome members (EXOSC7 and EXOSC8) can block the activity of EXOSC1 to cleave DNA. Therefore, a single EXOSC1 protein can show different responses depending on the presence/absence of its interacting partners. Further studies are needed to better understand the roles of the individual exosome member.</p><p>The potential pathological significance of EXOSC1 is supported by its association with poor DFS and OS in KIRC. Due to the capability of EXOSC1 to cleave DNA and promote mutations, EXOSC1 might enhance mutations and consequently provide genetic fuel for cancer development, metastasis, and even therapy resistance. Therefore, EXOSC1 might represent not only a KIRC marker but also a target to decrease the rate of KIRC evolution and stabilize the targets of existing therapeutics. Furthermore, targeting DNA repair in cancers by inhibiting PARPs offers an important therapeutic strategy (<xref ref-type="bibr" rid="bib10">Cleary et al., 2020</xref>). Unfortunately, the failure of PARP inhibitors to markedly benefit patients enforces the necessity for developing new strategies to improve their efficacy (<xref ref-type="bibr" rid="bib10">Cleary et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Dizon, 2017</xref>; <xref ref-type="bibr" rid="bib27">Lord and Ashworth, 2017</xref>). Our study demonstrated that EXOSC1 sensitized KIRC cells to PARP inhibitor, suggesting inhibition of PARPs might be a penitential strategy to treat KIRC patients with high EXOSC1. We also noticed that KIRC patients with high EXOSC1 and VHL mutations showed the poorest OS. Considering the DNA cleavage activity of EXOSC1 and the role of VHL in stabilizing the genome (<xref ref-type="bibr" rid="bib43">Thoma et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Zhang et al., 2018</xref>), we speculate that patients with the VHL mutation and high EXOSC1might show higher possibility to benefit from PARP inhibitor(s).</p><p>However, several limitations of this study should be noted. First, we observed a notable variation in terms of the correlation with a different c-substitution type for a given gene, implying the need for further studies. Second, although we showed that EXOSC1 could cleave ssDNA and act as an ESM, we did not directly identify the mechanism responsible for turning the DNA cleavages into mutations. The role of XRCC1 in EXOSC1-promoted mutations was only briefly evaluated. Hence, we cannot exclude the possibility that other proteins might contribute to this process. Third, the candidate ESM genes in KIRC showed notable enrichment in ‘mitochondrial gene expression’ and ‘organophosphate biosynthetic process’, suggesting a role of lipid metabolism. Unfortunately, due to the limitation of in vitro rifampicin-resistant assay, we did not focus on the lipid metabolism in this study. Since that KIRC cells are well known to contain many lipid droplets, it will be interesting to determine whether and how lipid metabolism acts as an ESM. Despite these limitations, our results still indicate that EXOSC1 acts as an ESM in KIRC.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Antibody</td><td valign="top">Anti-Flag (rabbit polyclonal)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat. number F7425 (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_439687">AB_439687</ext-link>)</td><td valign="top">Western blot (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-His (rabbit polyclonal)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat. number SAB1306085</td><td valign="top">Western blot (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-phospho-γ-H2AX (Ser139) (mouse monoclonal)</td><td valign="top">Millipore</td><td valign="top">Cat. number 05–636 (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_309864">AB_309864</ext-link>)</td><td valign="top">IF (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-XRCC1 (rabbit polyclonal)</td><td valign="top">Millipore</td><td valign="top">Cat. number ABE559</td><td valign="top">Western blot (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-EXOSC1 (rabbit monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat. number EPR13526</td><td valign="top">Western blot (1:1000)</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Niraparib</td><td valign="top">MedChem Express</td><td valign="top">Cat. number HY-10619</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Olaparib</td><td valign="top">MedChem Express</td><td valign="top">Cat. number HY-10162</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Rifampicin</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat. number R3501</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Prism</td><td valign="top">GraphPad</td><td valign="top">Version 8</td><td valign="top">data analyses</td></tr><tr><td valign="top">Other</td><td valign="top">Lipofectamine 2000</td><td valign="top">Thermo Fisher Scientific Inc</td><td valign="top">Cat. number 11668019</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Sample preparation</title><p>Samples of 532 KIRC patients from TCGA used for expression and mutation analyses were collected through The cBio Cancer Genomics Portal (<ext-link ext-link-type="uri" xlink:href="http://cbioportal.org">http://cbioportal.org</ext-link>) as described in our previous studies (<xref ref-type="bibr" rid="bib22">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Zhou et al., 2019</xref>).</p></sec><sec id="s4-2"><title>Cell culture</title><p>All cell lines were obtained from the American Type Tissue Collection. The 769 P, SNU-1272, and Caki-2 cells were maintained in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, and streptomycin at 37°C under a humidified atmosphere of 5% CO<sub>2</sub> Dulbecco's modified Eagle's medium containing 10% heat-inactivated FBS, 100 U/ml penicillin, and streptomycin at 37°C under a humidified atmosphere of 5% CO<sub>2</sub>. Mycoplasma PCR testing of these cells was performed every week, and no mycoplasma was detected. Transfections were performed using lipofectamine 2000 (Thermo Fisher Scientific Inc, Waltham, MA).</p></sec><sec id="s4-3"><title>Antibodies, reagents, and plasmids</title><p>Anti-Flag (cat. number F7425) and anti-His (cat. number SAB1306085) antibodies were from Sigma-Aldrich (St. Louis, MS). Anti-phospho-γ-H2AX (Ser139) (cat. number 05-636) and anti-XRCC1 (cat. number ABE559) were from Millipore (Billerica, MA). Anti-EXOSC1 (cat. number EPR13526) was from Abcam (Cambridge, MA). Niraparib (cat. number HY-10619) and olaparib (cat. number HY-10162) were from MedChem Express. Rifampicin (cat. number R3501) was from Sigma-Aldrich.</p><p>Full-length EXOSC1 was cloned into the X<italic>ba</italic> I and N<italic>he</italic> I sites of the lentivirus vector pCDH-CMV-MCS-EF1-Puro (System Biosciences, Mountain View, CA) to construct pCDH-Flag EXOSC1. <named-content content-type="sequence">CCGAGTTCCTACAGACCTAAG</named-content> and <named-content content-type="sequence">CGAGGAACTATCCGCAAAGAA</named-content> sequences were cloned into pLKO.1 to construct the pLKO shEXOSC1-1 and pLKO shEXOSC1-2 plasmids, respectively. Similarly, <named-content content-type="sequence">CCAGTGCTCCAGGAAGATATA</named-content> and <named-content content-type="sequence">CGATACGTCACAGCCTTCAAT</named-content> sequences were cloned into pMKO.1 to construct the pMKO shXRCC1-1 and pMKO shXRCC1-2 plasmids, respectively. According to the knockdown efficiency (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), pLKO shEXOSC1-1 and pMKO.1 shXRCC1-1 with higher knockdown efficiencies were used to generate EXOSC1-KD and XRCC1-KD cells. AID (NM_020661.4), CDK5 (NM_004935.4), TARBP2 (NM_134323.1), EXOSC1 (NM_016046.5), RAB5IF (NM_018840.5), CCNB1 (NM_031966.4), PSAT1 (NM_058179.4), NECAB3 (NM_031232.3), EXOSC2 (NM_014285.7), EXOSC3 (NM_016042.4), EXOSC4 (NM_019037.3), EXOSC5 (NM_020158.4), EXOSC6 (NM_058219.3), EXOSC7 (NM_015004.4), EXOSC8 (NM_181503.3), and EXOSC9 (NM_005033) were amplified and cloned into the pET-28a(+) vector (Novogen Limited, Hornsby Westfield, NSW) to construct the pET-28a-Gene-6XHis <italic>E. coli</italic> expression plasmids. PCR primers for the amplification of the above genes are described in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p></sec><sec id="s4-4"><title>Immunoblotting and immunofluorescence</title><p>Immunoblotting and immunofluorescence were carried out as described in our previous study (<xref ref-type="bibr" rid="bib42">Song et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Wang et al., 2020</xref>).</p></sec><sec id="s4-5"><title>Rifampicin-resistant assay in <italic>E. coli</italic></title><p>Rifampicin-resistant assays were carried out as described previously (<xref ref-type="bibr" rid="bib35">Petersen-Mahrt et al., 2002</xref>). Briefly, rifampicin-resistant assays for each gene were performed using 30 independent cultures grown overnight to saturation in a rich medium supplemented with 50 mg/L kanamycin and 1 mM IPTG. Rif<sup>R</sup> mutants were selected on a medium containing 50 mg/L rifampicin. Mutation frequencies were assessed by determining the median number of rifampicin-resistant clones per 10<sup>9</sup> viable plated cells. The mutation spectra of Rif<sup>R</sup> were analyzed by sequencing the amplified rpoB 627 bp PCR products using 5′-<named-content content-type="sequence">TTGGCGAAATGGCGGAAAACC</named-content>-3′ and 5′-<named-content content-type="sequence">CACCGACGGATACCACCTGCTG</named-content>-3′ primers.</p></sec><sec id="s4-6"><title>Expression and purification of EXOSC proteins</title><p>Expression and purification of EXOSC proteins were carried out as described in our previous study (<xref ref-type="bibr" rid="bib49">Wang et al., 2020</xref>). pET-28a-EXOSCs-6XHises encoding His-tagged EXOSCs were introduced into BL21 (DE3)-pLysS, which were grown in nutrient-rich medium with 32Y (containing 3.2% (w/v) yeast extract, 0.8% (w/v) peptone, and 0.58% (w/v) NaCl) in 10 mM Tris–HCl at 30°C and pH 7.4. Protein expression was induced with 0.4 mM IPTG at 20°C for 20 hr after the cells reached an OD<sub>600</sub> of 0.4–0.5. Induced BL21 (DE3)-pLysS host cells without any plasmid were used as a negative control. The resultant cells were harvested by centrifugation at 5000×<italic>g</italic> for 10 min and washed ttwice with ice-cold phosphate-buffered saline (PBS). The collected cells were resuspended in PBS (1 g of wet weight cells per 10 mL of PBS) containing 1 mM MgCl<sub>2</sub>, 20 mM imidazole, one tablet/50 mL protease inhibitor cocktail, and 100 U/mL DNase. Resuspended cells were broken by an ultrasonic wave. Cell lysates were centrifuged at 20,000×<italic>g</italic> at 4°C for 30 min to remove unbroken cells and debris.</p><p>After pre-equilibration with 10 column volumes (CVs) of binding buffer (PBS containing 10% (v/v) glycerol and 20 mM imidazole, pH 7.6), Ni sepharose 6 Fast flow (GE Healthcare, New York, NY) was applied for the purification of EXOSCs. The resins were washed five times and eluted using elution buffer (binding buffer containing 300 mM imidazole). EXOSCs were concentrated using an Amicon Ultrafree centrifugal filter (Millipore Corporation, Billerica, MA) and pre-equilibrated with 10 mM HEPES buffer (pH 7.4) containing 150 mM NaCl and 10% glycerol. Size-exclusion chromatography (SEC) with a Superdex-200 HiLoad 10/600 column was used to further purify EXOSCs. The purity of the fractions was analyzed by coomassie blue staining. The protein concentration was determined using a BCA assay according to the manufacturer’s instructions (Pierce, Rockland, IL).</p></sec><sec id="s4-7"><title>Cleavage activity assay in vitro</title><p>The cleavage assays of EXOSCs were carried out in reaction buffer modified from a previous study (<xref ref-type="bibr" rid="bib24">Liu et al., 2006</xref>). Briefly, 50 µL of reaction mixture containing 1 μM oligonucleotides, 1 μM EXOSC protein, 70 mM KCl, 700 μM MgCl<sub>2</sub>, 1 mM DTT, and 20 mM Tris–HCl pH 7.0 was incubated at 37°C for 4 hr. The reaction was stopped by addition of 10 μM proteinase K at 58°C for 10 min and heating at 90°C for 30 s. The resultant samples were then analyzed using 15% polyacrylamide TBE-urea gels.</p></sec><sec id="s4-8"><title>LC-MS/MS analysis</title><p>LC-MS/MS analyses of deoxyadenine (A), deoxythymidine (T), deoxyguanine (G), and deoxycytocine (C) were carried out as described in our previous studies (<xref ref-type="bibr" rid="bib42">Song et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Wang et al., 2020</xref>).</p></sec><sec id="s4-9"><title>Generation of stable cell lines</title><p>Stable cell lines were generated as described in our previous study (<xref ref-type="bibr" rid="bib42">Song et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Wang et al., 2020</xref>). Briefly, the TUHR14TKB, SNU-1272, 769 P, and Caki-2 cells were infected with pCDH-CMV-MCS-EF1-Puro (empty vector used as control), pCDH-Flag EXOSC1 (EXOSC1-OE), pLKO.1-scramble shRNA (empty vector used as control), pLKO shEXOSC1-1 (EXOSC1-KD), or pLKO shEXOSC1-2 lentiviral particles, which were generated following the manufacturer’s protocol (System Biosciences, Mountain View, CA). The resultant cells were selected with puromycin for 2 weeks. These stable cells were then infected with virus encoding pMKO.1, pMKO.1 shXRCC1-1 (XRCC1-KD), or pMKO.1 shXRCC1-2. The resultant cells were selected with hygromycin B for 2 weeks to generate stable XRCC1 knockdown cells. According to the knockdown efficiency (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), shEXOSC1-1 and shXRCC1-1 with higher knockdown efficiencies were used as EXOSC1-KD and XRCC1-KD in this study.</p></sec><sec id="s4-10"><title>γ-H2AX staining and neutral comet tail assays</title><p>γ-H2AX staining and neutral comet tail assays were performed as described previously (<xref ref-type="bibr" rid="bib22">Li et al., 2020</xref>).</p></sec><sec id="s4-11"><title>3D-PCR and sequencing</title><p>3D-PCRs of VHL mutations were carried out as described previously (<xref ref-type="bibr" rid="bib8">Burns et al., 2013a</xref>) using first (5′-<named-content content-type="sequence">GAGTACGGCCCTGAAGAAGA</named-content>-3′ and 5′-<named-content content-type="sequence">TCAATCTCCCATCCGTTGAT</named-content>-3′) and nested (5′-<named-content content-type="sequence">TGCGCTAGGTGAACTCGC</named-content>-3′ and 5′-<named-content content-type="sequence">GCGGCAGCGTTGGGTAGG</named-content>-3′) PCR primers. PCR products were then analyzed by gel electrophoresis, cloned into pMD20-T vector, and sequenced.</p></sec><sec id="s4-12"><title>Colony-forming assay</title><p>The colony-forming assays were performed as described in our previous study (<xref ref-type="bibr" rid="bib22">Li et al., 2020</xref>).</p></sec><sec id="s4-13"><title>Subcutaneous xenograft tumor growth in vivo</title><p>The following animal-handling procedures were approved by the Animal Care and Use Committee of Dalian Medical University. Xenograft models were carried out as described in our previous studies (<xref ref-type="bibr" rid="bib22">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Song et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Yang et al., 2010</xref>). Briefly, 2 × 10<sup>6</sup> stable control/EXOSC1-OE 769 P and Caki-2 cells were suspended and injected subcutaneously into the flank of 6-week-old nude mice. After 7 days, these tumor-bearing mice were randomized into four groups (six mice per group) and treated by oral gavage twice a day with vehicle or niraparib (4 mg/kg). The mice were observed daily and weighed once per week. Tumor size was measured using a caliper, and the tumor volume was calculated using the following formula: 0.52×L×W<sup>2</sup>, where L is the longest diameter and W is the shortest diameter. Mice were euthanized when the tumors reached 1500 mm<sup>3</sup> or showed necrosis.</p></sec><sec id="s4-14"><title>Statistical analyses</title><p>P values were calculated by the two-tailed Student’s <italic>t</italic>-test, log-rank test, Fisher's exact test, chi-squared test, or Spearman's correlation analyses as noted. P values&lt;0.05 were considered statistically significant.</p></sec><sec id="s4-15"><title>Experimental replicates and reproducibility</title><p>All data presented in this paper are representative of two to four independent experiments with comparable results.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors would like to thank Dr. Wei Cheng (ICSC Core Facility, Dalian Medical University) for her material and technical support. Funding: This study was supported by grants from the National Natural Science Foundation of China (NSFC Nos. 81872310 to QY, and 82073123 to CS) and the China Postdoctoral Science Foundation (2020M680956 to LW). The project is sponsored by Liaoning BaiQingWan Talents Program.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Supervision, Validation, Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Funding acquisition, Investigation, Writing - original draft</p></fn><fn fn-type="con" id="con9"><p>Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Table for the candidates identified by Spearman’s rank analyses at whole genomic level.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Table for the candidates identified by Student’s <italic>t</italic>-test analyses at whole genomic level.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Table for the genes showing significant association with VHL.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Table for the overlap numbers of the candidate genes of the six types of c-substitutions.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-supp4-v2.xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Table for primer sequence.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69454-supp5-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-69454-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data associated with this study are available in the main text or the supplementary materials.</p><p>The following previously published dataset was used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><data-title>Comprehensive molecular characterization of clear cell renal cell carcinoma</data-title><source>cBioPortal</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="http://www.cbioportal.org/study/summary?id=kirc_tcga_pub">KIRC</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Aparicio</surname> <given-names>SA</given-names></name><name><surname>Behjati</surname> <given-names>S</given-names></name><name><surname>Biankin</surname> <given-names>AV</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>Bolli</surname> <given-names>N</given-names></name><name><surname>Borg</surname> <given-names>A</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Boyault</surname> <given-names>S</given-names></name><name><surname>Burkhardt</surname> <given-names>B</given-names></name><name><surname>Butler</surname> <given-names>AP</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Davies</surname> <given-names>HR</given-names></name><name><surname>Desmedt</surname> <given-names>C</given-names></name><name><surname>Eils</surname> <given-names>R</given-names></name><name><surname>Eyfjörd</surname> <given-names>JE</given-names></name><name><surname>Foekens</surname> <given-names>JA</given-names></name><name><surname>Greaves</surname> <given-names>M</given-names></name><name><surname>Hosoda</surname> <given-names>F</given-names></name><name><surname>Hutter</surname> <given-names>B</given-names></name><name><surname>Ilicic</surname> <given-names>T</given-names></name><name><surname>Imbeaud</surname> <given-names>S</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Imielinsk</surname> <given-names>M</given-names></name><name><surname>Jäger</surname> <given-names>N</given-names></name><name><surname>Jones</surname> <given-names>DT</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Knappskog</surname> <given-names>S</given-names></name><name><surname>Kool</surname> <given-names>M</given-names></name><name><surname>Lakhani</surname> <given-names>SR</given-names></name><name><surname>López-Otín</surname> <given-names>C</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Munshi</surname> <given-names>NC</given-names></name><name><surname>Nakamura</surname> <given-names>H</given-names></name><name><surname>Northcott</surname> <given-names>PA</given-names></name><name><surname>Pajic</surname> <given-names>M</given-names></name><name><surname>Papaemmanuil</surname> <given-names>E</given-names></name><name><surname>Paradiso</surname> <given-names>A</given-names></name><name><surname>Pearson</surname> <given-names>JV</given-names></name><name><surname>Puente</surname> <given-names>XS</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Ramakrishna</surname> <given-names>M</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Richter</surname> <given-names>J</given-names></name><name><surname>Rosenstiel</surname> <given-names>P</given-names></name><name><surname>Schlesner</surname> <given-names>M</given-names></name><name><surname>Schumacher</surname> <given-names>TN</given-names></name><name><surname>Span</surname> <given-names>PN</given-names></name><name><surname>Teague</surname> <given-names>JW</given-names></name><name><surname>Totoki</surname> <given-names>Y</given-names></name><name><surname>Tutt</surname> <given-names>AN</given-names></name><name><surname>Valdés-Mas</surname> <given-names>R</given-names></name><name><surname>van Buuren</surname> <given-names>MM</given-names></name><name><surname>van 't Veer</surname> <given-names>L</given-names></name><name><surname>Vincent-Salomon</surname> <given-names>A</given-names></name><name><surname>Waddell</surname> <given-names>N</given-names></name><name><surname>Yates</surname> <given-names>LR</given-names></name><name><surname>Zucman-Rossi</surname> <given-names>J</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Lichter</surname> <given-names>P</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Grimmond</surname> <given-names>SM</given-names></name><name><surname>Siebert</surname> <given-names>R</given-names></name><name><surname>Campo</surname> <given-names>E</given-names></name><name><surname>Shibata</surname> <given-names>T</given-names></name><name><surname>Pfister</surname> <given-names>SM</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><collab>Australian Pancreatic Cancer Genome Initiative</collab><collab>ICGC Breast Cancer Consortium</collab><collab>ICGC MMML-Seq Consortium</collab><collab>ICGC PedBrain</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Signatures of mutational processes in human Cancer</article-title><source>Nature</source><volume>500</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nature12477</pub-id><pub-id pub-id-type="pmid">23945592</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barlow</surname> <given-names>JH</given-names></name><name><surname>Faryabi</surname> <given-names>RB</given-names></name><name><surname>Callén</surname> <given-names>E</given-names></name><name><surname>Wong</surname> <given-names>N</given-names></name><name><surname>Malhowski</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>HT</given-names></name><name><surname>Gutierrez-Cruz</surname> <given-names>G</given-names></name><name><surname>Sun</surname> <given-names>H-W</given-names></name><name><surname>McKinnon</surname> <given-names>P</given-names></name><name><surname>Wright</surname> <given-names>G</given-names></name><name><surname>Casellas</surname> <given-names>R</given-names></name><name><surname>Robbiani</surname> <given-names>DF</given-names></name><name><surname>Staudt</surname> <given-names>L</given-names></name><name><surname>Fernandez-Capetillo</surname> <given-names>O</given-names></name><name><surname>Nussenzweig</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of Early Replicating Fragile Sites that Contribute to Genome Instability</article-title><source>Cell</source><volume>152</volume><fpage>620</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.01.006</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet-Antonelli</surname> <given-names>C</given-names></name><name><surname>Presutti</surname> <given-names>C</given-names></name><name><surname>Tollervey</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification of a Regulated Pathway for Nuclear Pre-mRNA Turnover</article-title><source>Cell</source><volume>102</volume><fpage>765</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00065-9</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>JT</given-names></name><name><surname>Bai</surname> <given-names>X</given-names></name><name><surname>Johnson</surname> <given-names>AW</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The yeast antiviral proteins Ski2p, Ski3p, and Ski8p exist as a complex in vivo</article-title><source>RNA</source><volume>6</volume><fpage>449</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1017/S1355838200991787</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>JS</given-names></name><name><surname>O'Carrigan</surname> <given-names>B</given-names></name><name><surname>Jackson</surname> <given-names>SP</given-names></name><name><surname>Yap</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting DNA Repair in Cancer: Beyond PARP Inhibitors</article-title><source>Cancer Discovery</source><volume>7</volume><fpage>20</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0860</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buisson</surname> <given-names>R</given-names></name><name><surname>Langenbucher</surname> <given-names>A</given-names></name><name><surname>Bowen</surname> <given-names>D</given-names></name><name><surname>Kwan</surname> <given-names>EE</given-names></name><name><surname>Benes</surname> <given-names>CH</given-names></name><name><surname>Zou</surname> <given-names>L</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features</article-title><source>Science</source><volume>364</volume><elocation-id>eaaw2872</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaw2872</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Switching APOBEC mutation signatures</article-title><source>Nature Reviews Genetics</source><volume>20</volume><elocation-id>253</elocation-id><pub-id pub-id-type="doi">10.1038/s41576-019-0116-4</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname> <given-names>MB</given-names></name><name><surname>Lackey</surname> <given-names>L</given-names></name><name><surname>Carpenter</surname> <given-names>MA</given-names></name><name><surname>Rathore</surname> <given-names>A</given-names></name><name><surname>Land</surname> <given-names>AM</given-names></name><name><surname>Leonard</surname> <given-names>B</given-names></name><name><surname>Refsland</surname> <given-names>EW</given-names></name><name><surname>Kotandeniya</surname> <given-names>D</given-names></name><name><surname>Tretyakova</surname> <given-names>N</given-names></name><name><surname>Nikas</surname> <given-names>JB</given-names></name><name><surname>Yee</surname> <given-names>D</given-names></name><name><surname>Temiz</surname> <given-names>NA</given-names></name><name><surname>Donohue</surname> <given-names>DE</given-names></name><name><surname>McDougle</surname> <given-names>RM</given-names></name><name><surname>Brown</surname> <given-names>WL</given-names></name><name><surname>Law</surname> <given-names>EK</given-names></name><name><surname>Harris</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>APOBEC3B is an enzymatic source of mutation in breast Cancer</article-title><source>Nature</source><volume>494</volume><fpage>366</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1038/nature11881</pub-id><pub-id pub-id-type="pmid">23389445</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname> <given-names>MB</given-names></name><name><surname>Temiz</surname> <given-names>NA</given-names></name><name><surname>Harris</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Evidence for APOBEC3B mutagenesis in multiple human cancers</article-title><source>Nature Genetics</source><volume>45</volume><fpage>977</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1038/ng.2701</pub-id><pub-id pub-id-type="pmid">23852168</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleary</surname> <given-names>JM</given-names></name><name><surname>Aguirre</surname> <given-names>AJ</given-names></name><name><surname>Shapiro</surname> <given-names>GI</given-names></name><name><surname>D’Andrea</surname> <given-names>AD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Biomarker-Guided Development of DNA Repair Inhibitors</article-title><source>Molecular Cell</source><volume>78</volume><fpage>1070</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.04.035</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cvetkovic</surname> <given-names>MA</given-names></name><name><surname>Wurm</surname> <given-names>JP</given-names></name><name><surname>Audin</surname> <given-names>MJ</given-names></name><name><surname>Schütz</surname> <given-names>S</given-names></name><name><surname>Sprangers</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The Rrp4–exosome complex recruits and channels substrate RNA by a unique mechanism</article-title><source>Nature Chemical Biology</source><volume>13</volume><fpage>522</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2328</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname> <given-names>L</given-names></name><name><surname>Zhao</surname> <given-names>T</given-names></name><name><surname>Bisteau</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>W</given-names></name><name><surname>Prabhu</surname> <given-names>N</given-names></name><name><surname>Lim</surname> <given-names>YT</given-names></name><name><surname>Sobota</surname> <given-names>RM</given-names></name><name><surname>Kaldis</surname> <given-names>P</given-names></name><name><surname>Nordlund</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Modulation of Protein-Interaction States through the Cell Cycle</article-title><source>Cell</source><volume>173</volume><fpage>e1413</fpage><lpage>e1494</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.065</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dizon</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PARP inhibitors for targeted treatment in ovarian cancer</article-title><source>The Lancet</source><volume>390</volume><fpage>1929</fpage><lpage>1930</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)32418-2</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname> <given-names>H</given-names></name><name><surname>McCabe</surname> <given-names>N</given-names></name><name><surname>Lord</surname> <given-names>CJ</given-names></name><name><surname>Tutt</surname> <given-names>ANJ</given-names></name><name><surname>Johnson</surname> <given-names>DA</given-names></name><name><surname>Richardson</surname> <given-names>TB</given-names></name><name><surname>Santarosa</surname> <given-names>M</given-names></name><name><surname>Dillon</surname> <given-names>KJ</given-names></name><name><surname>Hickson</surname> <given-names>I</given-names></name><name><surname>Knights</surname> <given-names>C</given-names></name><name><surname>Martin</surname> <given-names>NMB</given-names></name><name><surname>Jackson</surname> <given-names>SP</given-names></name><name><surname>Smith</surname> <given-names>GCM</given-names></name><name><surname>Ashworth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title><source>Nature</source><volume>434</volume><fpage>917</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1038/nature03445</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greaves</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A causal mechanism for childhood acute lymphoblastic leukaemia</article-title><source>Nature Reviews Cancer</source><volume>18</volume><fpage>471</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0015-6</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houseley</surname> <given-names>J</given-names></name><name><surname>LaCava</surname> <given-names>J</given-names></name><name><surname>Tollervey</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>RNA-quality control by the exosome</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>7</volume><fpage>529</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1038/nrm1964</pub-id><pub-id pub-id-type="pmid">16829983</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchinson</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Signatures of mutational processes in cancer—a big step closer</article-title><source>Nature Reviews Clinical Oncology</source><volume>10</volume><elocation-id>545</elocation-id><pub-id pub-id-type="doi">10.1038/nrclinonc.2013.162</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Januszyk</surname> <given-names>K</given-names></name><name><surname>Lima</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The eukaryotic RNA exosome</article-title><source>Current Opinion in Structural Biology</source><volume>24</volume><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2014.01.011</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeggo</surname> <given-names>PA</given-names></name><name><surname>Pearl</surname> <given-names>LH</given-names></name><name><surname>Carr</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>DNA repair, genome stability and Cancer: a historical perspective</article-title><source>Nature Reviews Cancer</source><volume>16</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/nrc.2015.4</pub-id><pub-id pub-id-type="pmid">26667849</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>McLellan</surname> <given-names>MD</given-names></name><name><surname>Vandin</surname> <given-names>F</given-names></name><name><surname>Ye</surname> <given-names>K</given-names></name><name><surname>Niu</surname> <given-names>B</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Xie</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>McMichael</surname> <given-names>JF</given-names></name><name><surname>Wyczalkowski</surname> <given-names>MA</given-names></name><name><surname>Leiserson</surname> <given-names>MDM</given-names></name><name><surname>Miller</surname> <given-names>CA</given-names></name><name><surname>Welch</surname> <given-names>JS</given-names></name><name><surname>Walter</surname> <given-names>MJ</given-names></name><name><surname>Wendl</surname> <given-names>MC</given-names></name><name><surname>Ley</surname> <given-names>TJ</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Raphael</surname> <given-names>BJ</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational landscape and significance across 12 major cancer types</article-title><source>Nature</source><volume>502</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nature12634</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilchert</surname> <given-names>C</given-names></name><name><surname>Wittmann</surname> <given-names>S</given-names></name><name><surname>Vasiljeva</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The regulation and functions of the nuclear RNA exosome complex</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>17</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/nrm.2015.15</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>N</given-names></name><name><surname>Guo</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Lv</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>Q-k</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><elocation-id>219</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-2408-1</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>J</given-names></name><name><surname>Giri</surname> <given-names>PK</given-names></name><name><surname>Kazadi</surname> <given-names>D</given-names></name><name><surname>Laffleur</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Grinstein</surname> <given-names>V</given-names></name><name><surname>Pefanis</surname> <given-names>E</given-names></name><name><surname>Brown</surname> <given-names>LM</given-names></name><name><surname>Ladewig</surname> <given-names>E</given-names></name><name><surname>Martin</surname> <given-names>O</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Rabadan</surname> <given-names>R</given-names></name><name><surname>Boyer</surname> <given-names>F</given-names></name><name><surname>Rothschild</surname> <given-names>G</given-names></name><name><surname>Cogné</surname> <given-names>M</given-names></name><name><surname>Pinaud</surname> <given-names>E</given-names></name><name><surname>Deng</surname> <given-names>H</given-names></name><name><surname>Basu</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nuclear Proximity of Mtr4 to RNA Exosome Restricts DNA Mutational Asymmetry</article-title><source>Cell</source><volume>169</volume><fpage>e515</fpage><lpage>e537</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.03.043</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Greimann</surname> <given-names>JC</given-names></name><name><surname>Lima</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Reconstitution, activities, and structure of the eukaryotic RNA exosome</article-title><source>Cell</source><volume>127</volume><fpage>1223</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.10.037</pub-id><pub-id pub-id-type="pmid">17174896</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human cancers express mutator phenotypes: origin, consequences and targeting</article-title><source>Nature Reviews Cancer</source><volume>11</volume><fpage>450</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/nrc3063</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname> <given-names>CJ</given-names></name><name><surname>Ashworth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The DNA damage response and cancer therapy</article-title><source>Nature</source><volume>481</volume><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1038/nature10760</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname> <given-names>CJ</given-names></name><name><surname>Ashworth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PARP inhibitors: Synthetic lethality in the clinic</article-title><source>Science</source><volume>355</volume><fpage>1152</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1126/science.aam7344</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorentzen</surname> <given-names>E</given-names></name><name><surname>Basquin</surname> <given-names>J</given-names></name><name><surname>Tomecki</surname> <given-names>R</given-names></name><name><surname>Dziembowski</surname> <given-names>A</given-names></name><name><surname>Conti</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Structure of the Active Subunit of the Yeast Exosome Core, Rrp44: Diverse Modes of Substrate Recruitment in the RNase II Nuclease Family</article-title><source>Molecular Cell</source><volume>29</volume><fpage>717</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.02.018</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malet</surname> <given-names>H</given-names></name><name><surname>Topf</surname> <given-names>M</given-names></name><name><surname>Clare</surname> <given-names>DK</given-names></name><name><surname>Ebert</surname> <given-names>J</given-names></name><name><surname>Bonneau</surname> <given-names>F</given-names></name><name><surname>Basquin</surname> <given-names>J</given-names></name><name><surname>Drazkowska</surname> <given-names>K</given-names></name><name><surname>Tomecki</surname> <given-names>R</given-names></name><name><surname>Dziembowski</surname> <given-names>A</given-names></name><name><surname>Conti</surname> <given-names>E</given-names></name><name><surname>Saibil</surname> <given-names>HR</given-names></name><name><surname>Lorentzen</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RNA channelling by the eukaryotic exosome</article-title><source>EMBO Reports</source><volume>11</volume><fpage>936</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1038/embor.2010.164</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname> <given-names>N</given-names></name><name><surname>Rosenthal</surname> <given-names>R</given-names></name><name><surname>Hiley</surname> <given-names>CT</given-names></name><name><surname>Rowan</surname> <given-names>AJ</given-names></name><name><surname>Watkins</surname> <given-names>TBK</given-names></name><name><surname>Wilson</surname> <given-names>GA</given-names></name><name><surname>Birkbak</surname> <given-names>NJ</given-names></name><name><surname>Veeriah</surname> <given-names>S</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Herrero</surname> <given-names>J</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name><name><surname>Jamal-Hanjani</surname> <given-names>M</given-names></name><name><surname>Veeriah</surname> <given-names>S</given-names></name><name><surname>Shafi</surname> <given-names>S</given-names></name><name><surname>Czyzewska-Khan</surname> <given-names>J</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Laycock</surname> <given-names>J</given-names></name><name><surname>Bosshard-Carter</surname> <given-names>L</given-names></name><name><surname>Rosenthal</surname> <given-names>R</given-names></name><name><surname>Gorman</surname> <given-names>P</given-names></name><name><surname>Hynds</surname> <given-names>RE</given-names></name><name><surname>Wilson</surname> <given-names>G</given-names></name><name><surname>Birkbak</surname> <given-names>NJ</given-names></name><name><surname>Watkins</surname> <given-names>TBK</given-names></name><name><surname>McGranahan</surname> <given-names>N</given-names></name><name><surname>Horswell</surname> <given-names>S</given-names></name><name><surname>Mitter</surname> <given-names>R</given-names></name><name><surname>Escudero</surname> <given-names>M</given-names></name><name><surname>Stewart</surname> <given-names>A</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Rowan</surname> <given-names>A</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Turajlic</surname> <given-names>S</given-names></name><name><surname>Hiley</surname> <given-names>C</given-names></name><name><surname>Abbosh</surname> <given-names>C</given-names></name><name><surname>Goldman</surname> <given-names>J</given-names></name><name><surname>Stone</surname> <given-names>RK</given-names></name><name><surname>Denner</surname> <given-names>T</given-names></name><name><surname>Matthews</surname> <given-names>N</given-names></name><name><surname>Elgar</surname> <given-names>G</given-names></name><name><surname>Ward</surname> <given-names>S</given-names></name><name><surname>Costa</surname> <given-names>M</given-names></name><name><surname>Begum</surname> <given-names>S</given-names></name><name><surname>Phillimore</surname> <given-names>B</given-names></name><name><surname>Chambers</surname> <given-names>T</given-names></name><name><surname>Nye</surname> <given-names>E</given-names></name><name><surname>Graca</surname> <given-names>S</given-names></name><name><surname>Al Bakir</surname> <given-names>M</given-names></name><name><surname>Joshi</surname> <given-names>K</given-names></name><name><surname>Furness</surname> <given-names>A</given-names></name><name><surname>Ben Aissa</surname> <given-names>A</given-names></name><name><surname>Wong</surname> <given-names>YNS</given-names></name><name><surname>Georgiou</surname> <given-names>A</given-names></name><name><surname>Quezada</surname> <given-names>S</given-names></name><name><surname>Hartley</surname> <given-names>JA</given-names></name><name><surname>Lowe</surname> <given-names>HL</given-names></name><name><surname>Herrero</surname> <given-names>J</given-names></name><name><surname>Lawrence</surname> <given-names>D</given-names></name><name><surname>Hayward</surname> <given-names>M</given-names></name><name><surname>Panagiotopoulos</surname> <given-names>N</given-names></name><name><surname>Kolvekar</surname> <given-names>S</given-names></name><name><surname>Falzon</surname> <given-names>M</given-names></name><name><surname>Borg</surname> <given-names>E</given-names></name><name><surname>Marafioti</surname> <given-names>T</given-names></name><name><surname>Simeon</surname> <given-names>C</given-names></name><name><surname>Hector</surname> <given-names>G</given-names></name><name><surname>Smith</surname> <given-names>A</given-names></name><name><surname>Aranda</surname> <given-names>M</given-names></name><name><surname>Novelli</surname> <given-names>M</given-names></name><name><surname>Oukrif</surname> <given-names>D</given-names></name><name><surname>Janes</surname> <given-names>SM</given-names></name><name><surname>Thakrar</surname> <given-names>R</given-names></name><name><surname>Forster</surname> <given-names>M</given-names></name><name><surname>Ahmad</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>SM</given-names></name><name><surname>Papadatos-Pastos</surname> <given-names>D</given-names></name><name><surname>Carnell</surname> <given-names>D</given-names></name><name><surname>Mendes</surname> <given-names>R</given-names></name><name><surname>George</surname> <given-names>J</given-names></name><name><surname>Navani</surname> <given-names>N</given-names></name><name><surname>Ahmed</surname> <given-names>A</given-names></name><name><surname>Taylor</surname> <given-names>M</given-names></name><name><surname>Choudhary</surname> <given-names>J</given-names></name><name><surname>Summers</surname> <given-names>Y</given-names></name><name><surname>Califano</surname> <given-names>R</given-names></name><name><surname>Taylor</surname> <given-names>P</given-names></name><name><surname>Shah</surname> <given-names>R</given-names></name><name><surname>Krysiak</surname> <given-names>P</given-names></name><name><surname>Rammohan</surname> <given-names>K</given-names></name><name><surname>Fontaine</surname> <given-names>E</given-names></name><name><surname>Booton</surname> <given-names>R</given-names></name><name><surname>Evison</surname> <given-names>M</given-names></name><name><surname>Crosbie</surname> <given-names>P</given-names></name><name><surname>Moss</surname> <given-names>S</given-names></name><name><surname>Idries</surname> <given-names>F</given-names></name><name><surname>Joseph</surname> <given-names>L</given-names></name><name><surname>Bishop</surname> <given-names>P</given-names></name><name><surname>Chaturved</surname> <given-names>A</given-names></name><name><surname>Quinn</surname> <given-names>AM</given-names></name><name><surname>Doran</surname> <given-names>H</given-names></name><name><surname>Leek</surname> <given-names>A</given-names></name><name><surname>Harrison</surname> <given-names>P</given-names></name><name><surname>Moore</surname> <given-names>K</given-names></name><name><surname>Waddington</surname> <given-names>R</given-names></name><name><surname>Novasio</surname> <given-names>J</given-names></name><name><surname>Blackhall</surname> <given-names>F</given-names></name><name><surname>Rogan</surname> <given-names>J</given-names></name><name><surname>Smith</surname> <given-names>E</given-names></name><name><surname>Dive</surname> <given-names>C</given-names></name><name><surname>Tugwood</surname> <given-names>J</given-names></name><name><surname>Brady</surname> <given-names>G</given-names></name><name><surname>Rothwell</surname> <given-names>DG</given-names></name><name><surname>Chemi</surname> <given-names>F</given-names></name><name><surname>Pierce</surname> <given-names>J</given-names></name><name><surname>Gulati</surname> <given-names>S</given-names></name><name><surname>Naidu</surname> <given-names>B</given-names></name><name><surname>Langman</surname> <given-names>G</given-names></name><name><surname>Trotter</surname> <given-names>S</given-names></name><name><surname>Bellamy</surname> <given-names>M</given-names></name><name><surname>Bancroft</surname> <given-names>H</given-names></name><name><surname>Kerr</surname> <given-names>A</given-names></name><name><surname>Kadiri</surname> <given-names>S</given-names></name><name><surname>Webb</surname> <given-names>J</given-names></name><name><surname>Middleton</surname> <given-names>G</given-names></name><name><surname>Djearaman</surname> <given-names>M</given-names></name><name><surname>Fennell</surname> <given-names>D</given-names></name><name><surname>Shaw</surname> <given-names>JA</given-names></name><name><surname>Le Quesne</surname> <given-names>J</given-names></name><name><surname>Moore</surname> <given-names>D</given-names></name><name><surname>Nakas</surname> <given-names>A</given-names></name><name><surname>Rathinam</surname> <given-names>S</given-names></name><name><surname>Monteiro</surname> <given-names>W</given-names></name><name><surname>Marshall</surname> <given-names>H</given-names></name><name><surname>Nelson</surname> <given-names>L</given-names></name><name><surname>Bennett</surname> <given-names>J</given-names></name><name><surname>Riley</surname> <given-names>J</given-names></name><name><surname>Primrose</surname> <given-names>L</given-names></name><name><surname>Martinson</surname> <given-names>L</given-names></name><name><surname>Anand</surname> <given-names>G</given-names></name><name><surname>Khan</surname> <given-names>S</given-names></name><name><surname>Amadi</surname> <given-names>A</given-names></name><name><surname>Nicolson</surname> <given-names>M</given-names></name><name><surname>Kerr</surname> <given-names>K</given-names></name><name><surname>Palmer</surname> <given-names>S</given-names></name><name><surname>Remmen</surname> <given-names>H</given-names></name><name><surname>Miller</surname> <given-names>J</given-names></name><name><surname>Buchan</surname> <given-names>K</given-names></name><name><surname>Chetty</surname> <given-names>M</given-names></name><name><surname>Gomersall</surname> <given-names>L</given-names></name><name><surname>Lester</surname> <given-names>J</given-names></name><name><surname>Edwards</surname> <given-names>A</given-names></name><name><surname>Morgan</surname> <given-names>F</given-names></name><name><surname>Adams</surname> <given-names>H</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Kornaszewska</surname> <given-names>M</given-names></name><name><surname>Attanoos</surname> <given-names>R</given-names></name><name><surname>Lock</surname> <given-names>S</given-names></name><name><surname>Verjee</surname> <given-names>A</given-names></name><name><surname>MacKenzie</surname> <given-names>M</given-names></name><name><surname>Wilcox</surname> <given-names>M</given-names></name><name><surname>Bell</surname> <given-names>H</given-names></name><name><surname>Hackshaw</surname> <given-names>A</given-names></name><name><surname>Ngai</surname> <given-names>Y</given-names></name><name><surname>Smith</surname> <given-names>S</given-names></name><name><surname>Gower</surname> <given-names>N</given-names></name><name><surname>Ottensmeier</surname> <given-names>C</given-names></name><name><surname>Chee</surname> <given-names>S</given-names></name><name><surname>Johnson</surname> <given-names>B</given-names></name><name><surname>Alzetani</surname> <given-names>A</given-names></name><name><surname>Shaw</surname> <given-names>E</given-names></name><name><surname>Lim</surname> <given-names>E</given-names></name><name><surname>De Sousa</surname> <given-names>P</given-names></name><name><surname>Barbosa</surname> <given-names>MT</given-names></name><name><surname>Bowman</surname> <given-names>A</given-names></name><name><surname>Jordan</surname> <given-names>S</given-names></name><name><surname>Rice</surname> <given-names>A</given-names></name><name><surname>Raubenheimer</surname> <given-names>H</given-names></name><name><surname>Proli</surname> <given-names>C</given-names></name><name><surname>Cufari</surname> <given-names>ME</given-names></name><name><surname>Ronquillo</surname> <given-names>JC</given-names></name><name><surname>Kwayie</surname> <given-names>A</given-names></name><name><surname>Bhayani</surname> <given-names>H</given-names></name><name><surname>Hamilton</surname> <given-names>M</given-names></name><name><surname>Bakar</surname> <given-names>Y</given-names></name><name><surname>Mensah</surname> <given-names>N</given-names></name><name><surname>Ambrose</surname> <given-names>L</given-names></name><name><surname>Devaraj</surname> <given-names>A</given-names></name><name><surname>Buderi</surname> <given-names>S</given-names></name><name><surname>Finch</surname> <given-names>J</given-names></name><name><surname>Azcarate</surname> <given-names>L</given-names></name><name><surname>Chavan</surname> <given-names>H</given-names></name><name><surname>Green</surname> <given-names>S</given-names></name><name><surname>Mashinga</surname> <given-names>H</given-names></name><name><surname>Nicholson</surname> <given-names>AG</given-names></name><name><surname>Lau</surname> <given-names>K</given-names></name><name><surname>Sheaff</surname> <given-names>M</given-names></name><name><surname>Schmid</surname> <given-names>P</given-names></name><name><surname>Conibear</surname> <given-names>J</given-names></name><name><surname>Ezhil</surname> <given-names>V</given-names></name><name><surname>Ismail</surname> <given-names>B</given-names></name><name><surname>Irvin-sellers</surname> <given-names>M</given-names></name><name><surname>Prakash</surname> <given-names>V</given-names></name><name><surname>Russell</surname> <given-names>P</given-names></name><name><surname>Light</surname> <given-names>T</given-names></name><name><surname>Horey</surname> <given-names>T</given-names></name><name><surname>Danson</surname> <given-names>S</given-names></name><name><surname>Bury</surname> <given-names>J</given-names></name><name><surname>Edwards</surname> <given-names>J</given-names></name><name><surname>Hill</surname> <given-names>J</given-names></name><name><surname>Matthews</surname> <given-names>S</given-names></name><name><surname>Kitsanta</surname> <given-names>Y</given-names></name><name><surname>Suvarna</surname> <given-names>K</given-names></name><name><surname>Fisher</surname> <given-names>P</given-names></name><name><surname>Keerio</surname> <given-names>AD</given-names></name><name><surname>Shackcloth</surname> <given-names>M</given-names></name><name><surname>Gosney</surname> <given-names>J</given-names></name><name><surname>Postmus</surname> <given-names>P</given-names></name><name><surname>Feeney</surname> <given-names>S</given-names></name><name><surname>Asante-Siaw</surname> <given-names>J</given-names></name><name><surname>Aerts</surname> <given-names>HJWL</given-names></name><name><surname>Dentro</surname> <given-names>S</given-names></name><name><surname>Dessimoz</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution</article-title><source>Cell</source><volume>171</volume><fpage>e1211</fpage><lpage>e1271</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.001</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearl</surname> <given-names>LH</given-names></name><name><surname>Schierz</surname> <given-names>AC</given-names></name><name><surname>Ward</surname> <given-names>SE</given-names></name><name><surname>Al-Lazikani</surname> <given-names>B</given-names></name><name><surname>Pearl</surname> <given-names>FMG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Therapeutic opportunities within the DNA damage response</article-title><source>Nature Reviews Cancer</source><volume>15</volume><fpage>166</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/nrc3891</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pefanis</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Rothschild</surname> <given-names>G</given-names></name><name><surname>Lim</surname> <given-names>J</given-names></name><name><surname>Kazadi</surname> <given-names>D</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Federation</surname> <given-names>A</given-names></name><name><surname>Chao</surname> <given-names>J</given-names></name><name><surname>Elliott</surname> <given-names>O</given-names></name><name><surname>Liu</surname> <given-names>ZP</given-names></name><name><surname>Economides</surname> <given-names>AN</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Rabadan</surname> <given-names>R</given-names></name><name><surname>Basu</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity</article-title><source>Cell</source><volume>161</volume><fpage>774</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.04.034</pub-id><pub-id pub-id-type="pmid">25957685</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pefanis</surname> <given-names>E</given-names></name><name><surname>Basu</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RNA exosome regulates AID DNA mutator activity in the B cell genome</article-title><source>Advances in Immunology</source><volume>127</volume><fpage>257</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/bs.ai.2015.04.002</pub-id><pub-id pub-id-type="pmid">26073986</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>L</given-names></name><name><surname>Bian</surname> <given-names>XW</given-names></name><name><surname>Li</surname> <given-names>DK</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>GM</given-names></name><name><surname>Xia</surname> <given-names>QY</given-names></name><name><surname>Xiong</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>13413</elocation-id><pub-id pub-id-type="doi">10.1038/srep13413</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen-Mahrt</surname> <given-names>SK</given-names></name><name><surname>Harris</surname> <given-names>RS</given-names></name><name><surname>Neuberger</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification</article-title><source>Nature</source><volume>418</volume><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/nature00862</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petljak</surname> <given-names>M</given-names></name><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Brammeld</surname> <given-names>JS</given-names></name><name><surname>Price</surname> <given-names>S</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Grossmann</surname> <given-names>S</given-names></name><name><surname>Dawson</surname> <given-names>KJ</given-names></name><name><surname>Ju</surname> <given-names>YS</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Tubio</surname> <given-names>JMC</given-names></name><name><surname>Koh</surname> <given-names>CC</given-names></name><name><surname>Georgakopoulos-Soares</surname> <given-names>I</given-names></name><name><surname>Rodríguez–Martín</surname> <given-names>B</given-names></name><name><surname>Otlu</surname> <given-names>B</given-names></name><name><surname>O’Meara</surname> <given-names>S</given-names></name><name><surname>Butler</surname> <given-names>AP</given-names></name><name><surname>Menzies</surname> <given-names>A</given-names></name><name><surname>Bhosle</surname> <given-names>SG</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Jones</surname> <given-names>DR</given-names></name><name><surname>Teague</surname> <given-names>JW</given-names></name><name><surname>Beal</surname> <given-names>K</given-names></name><name><surname>Latimer</surname> <given-names>C</given-names></name><name><surname>O’Neill</surname> <given-names>L</given-names></name><name><surname>Zamora</surname> <given-names>J</given-names></name><name><surname>Anderson</surname> <given-names>E</given-names></name><name><surname>Patel</surname> <given-names>N</given-names></name><name><surname>Maddison</surname> <given-names>M</given-names></name><name><surname>Ng</surname> <given-names>BL</given-names></name><name><surname>Graham</surname> <given-names>J</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis</article-title><source>Cell</source><volume>176</volume><fpage>e1220</fpage><lpage>e1294</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.02.012</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname> <given-names>SA</given-names></name><name><surname>Gordenin</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hypermutation in human cancer genomes: footprints and mechanisms</article-title><source>Nature Reviews Cancer</source><volume>14</volume><fpage>786</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1038/nrc3816</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname> <given-names>AG</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Al-Ahmadie</surname> <given-names>H</given-names></name><name><surname>Bellmunt</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>G</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Hinoue</surname> <given-names>T</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>Akbani</surname> <given-names>R</given-names></name><name><surname>Castro</surname> <given-names>MAA</given-names></name><name><surname>Gibb</surname> <given-names>EA</given-names></name><name><surname>Kanchi</surname> <given-names>RS</given-names></name><name><surname>Gordenin</surname> <given-names>DA</given-names></name><name><surname>Shukla</surname> <given-names>SA</given-names></name><name><surname>Sanchez-Vega</surname> <given-names>F</given-names></name><name><surname>Hansel</surname> <given-names>DE</given-names></name><name><surname>Czerniak</surname> <given-names>BA</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name><name><surname>Su</surname> <given-names>X</given-names></name><name><surname>de Sa Carvalho</surname> <given-names>B</given-names></name><name><surname>Chagas</surname> <given-names>VS</given-names></name><name><surname>Mungall</surname> <given-names>KL</given-names></name><name><surname>Sadeghi</surname> <given-names>S</given-names></name><name><surname>Pedamallu</surname> <given-names>CS</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Klimczak</surname> <given-names>LJ</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Choo</surname> <given-names>C</given-names></name><name><surname>Ojesina</surname> <given-names>AI</given-names></name><name><surname>Bullman</surname> <given-names>S</given-names></name><name><surname>Leraas</surname> <given-names>KM</given-names></name><name><surname>Lichtenberg</surname> <given-names>TM</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>McConkey</surname> <given-names>DJ</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Kwiatkowski</surname> <given-names>DJ</given-names></name><name><surname>Lerner</surname> <given-names>SP</given-names></name><name><surname>Akbani</surname> <given-names>R</given-names></name><name><surname>Al-Ahmadie</surname> <given-names>H</given-names></name><name><surname>Albert</surname> <given-names>M</given-names></name><name><surname>Alexopoulou</surname> <given-names>I</given-names></name><name><surname>Ally</surname> <given-names>A</given-names></name><name><surname>Antic</surname> <given-names>T</given-names></name><name><surname>Aron</surname> <given-names>M</given-names></name><name><surname>Balasundaram</surname> <given-names>M</given-names></name><name><surname>Bartlett</surname> <given-names>J</given-names></name><name><surname>Baylin</surname> <given-names>SB</given-names></name><name><surname>Beaver</surname> <given-names>A</given-names></name><name><surname>Bellmunt</surname> <given-names>J</given-names></name><name><surname>Birol</surname> <given-names>I</given-names></name><name><surname>Boice</surname> <given-names>L</given-names></name><name><surname>Bootwalla</surname> <given-names>MS</given-names></name><name><surname>Bowen</surname> <given-names>J</given-names></name><name><surname>Bowlby</surname> <given-names>R</given-names></name><name><surname>Brooks</surname> <given-names>D</given-names></name><name><surname>Broom</surname> <given-names>BM</given-names></name><name><surname>Bshara</surname> <given-names>W</given-names></name><name><surname>Bullman</surname> <given-names>S</given-names></name><name><surname>Burks</surname> <given-names>E</given-names></name><name><surname>Cárcano</surname> <given-names>FM</given-names></name><name><surname>Carlsen</surname> <given-names>R</given-names></name><name><surname>Carvalho</surname> <given-names>BS</given-names></name><name><surname>Carvalho</surname> <given-names>AL</given-names></name><name><surname>Castle</surname> <given-names>EP</given-names></name><name><surname>Castro</surname> <given-names>MAA</given-names></name><name><surname>Castro</surname> <given-names>P</given-names></name><name><surname>Catto</surname> <given-names>JW</given-names></name><name><surname>Chagas</surname> <given-names>VS</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Chesla</surname> <given-names>DW</given-names></name><name><surname>Choo</surname> <given-names>C</given-names></name><name><surname>Chuah</surname> <given-names>E</given-names></name><name><surname>Chudamani</surname> <given-names>S</given-names></name><name><surname>Cortessis</surname> <given-names>VK</given-names></name><name><surname>Cottingham</surname> <given-names>SL</given-names></name><name><surname>Crain</surname> <given-names>D</given-names></name><name><surname>Curley</surname> <given-names>E</given-names></name><name><surname>Czerniak</surname> <given-names>BA</given-names></name><name><surname>Daneshmand</surname> <given-names>S</given-names></name><name><surname>Demchok</surname> <given-names>JA</given-names></name><name><surname>Dhalla</surname> <given-names>N</given-names></name><name><surname>Djaladat</surname> <given-names>H</given-names></name><name><surname>Eckman</surname> <given-names>J</given-names></name><name><surname>Egea</surname> <given-names>SC</given-names></name><name><surname>Engel</surname> <given-names>J</given-names></name><name><surname>Felau</surname> <given-names>I</given-names></name><name><surname>Ferguson</surname> <given-names>ML</given-names></name><name><surname>Gardner</surname> <given-names>J</given-names></name><name><surname>Gastier-Foster</surname> <given-names>JM</given-names></name><name><surname>Gerken</surname> <given-names>M</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Gibb</surname> <given-names>EA</given-names></name><name><surname>Gomez-Fernandez</surname> <given-names>CR</given-names></name><name><surname>Gordenin</surname> <given-names>DA</given-names></name><name><surname>Guo</surname> <given-names>G</given-names></name><name><surname>Hansel</surname> <given-names>DE</given-names></name><name><surname>Harr</surname> <given-names>J</given-names></name><name><surname>Hartmann</surname> <given-names>A</given-names></name><name><surname>Herbert</surname> <given-names>LM</given-names></name><name><surname>Hinoue</surname> <given-names>T</given-names></name><name><surname>Ho</surname> <given-names>TH</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>Holt</surname> <given-names>RA</given-names></name><name><surname>Hutter</surname> <given-names>CM</given-names></name><name><surname>Jones</surname> <given-names>SJM</given-names></name><name><surname>Jorda</surname> <given-names>M</given-names></name><name><surname>Kahnoski</surname> <given-names>RJ</given-names></name><name><surname>Kanchi</surname> <given-names>RS</given-names></name><name><surname>Kasaian</surname> <given-names>K</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Klimczak</surname> <given-names>LJ</given-names></name><name><surname>Kwiatkowski</surname> <given-names>DJ</given-names></name><name><surname>Lai</surname> <given-names>PH</given-names></name><name><surname>Laird</surname> <given-names>PW</given-names></name><name><surname>Lane</surname> <given-names>BR</given-names></name><name><surname>Leraas</surname> <given-names>KM</given-names></name><name><surname>Lerner</surname> <given-names>SP</given-names></name><name><surname>Lichtenberg</surname> <given-names>TM</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Lolla</surname> <given-names>L</given-names></name><name><surname>Lotan</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Lucchesi</surname> <given-names>FR</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Machado</surname> <given-names>RD</given-names></name><name><surname>Maglinte</surname> <given-names>DT</given-names></name><name><surname>Mallery</surname> <given-names>D</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>Martin</surname> <given-names>SE</given-names></name><name><surname>Mayo</surname> <given-names>M</given-names></name><name><surname>McConkey</surname> <given-names>DJ</given-names></name><name><surname>Meraney</surname> <given-names>A</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Moinzadeh</surname> <given-names>A</given-names></name><name><surname>Moore</surname> <given-names>RA</given-names></name><name><surname>Mora Pinero</surname> <given-names>EM</given-names></name><name><surname>Morris</surname> <given-names>S</given-names></name><name><surname>Morrison</surname> <given-names>C</given-names></name><name><surname>Mungall</surname> <given-names>KL</given-names></name><name><surname>Mungall</surname> <given-names>AJ</given-names></name><name><surname>Myers</surname> <given-names>JB</given-names></name><name><surname>Naresh</surname> <given-names>R</given-names></name><name><surname>O'Donnell</surname> <given-names>PH</given-names></name><name><surname>Ojesina</surname> <given-names>AI</given-names></name><name><surname>Parekh</surname> <given-names>DJ</given-names></name><name><surname>Parfitt</surname> <given-names>J</given-names></name><name><surname>Paulauskis</surname> <given-names>JD</given-names></name><name><surname>Sekhar Pedamallu</surname> <given-names>C</given-names></name><name><surname>Penny</surname> <given-names>RJ</given-names></name><name><surname>Pihl</surname> <given-names>T</given-names></name><name><surname>Porten</surname> <given-names>S</given-names></name><name><surname>Quintero-Aguilo</surname> <given-names>ME</given-names></name><name><surname>Ramirez</surname> <given-names>NC</given-names></name><name><surname>Rathmell</surname> <given-names>WK</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name><name><surname>Rieger-Christ</surname> <given-names>K</given-names></name><name><surname>Robertson</surname> <given-names>AG</given-names></name><name><surname>Sadeghi</surname> <given-names>S</given-names></name><name><surname>Saller</surname> <given-names>C</given-names></name><name><surname>Salner</surname> <given-names>A</given-names></name><name><surname>Sanchez-Vega</surname> <given-names>F</given-names></name><name><surname>Sandusky</surname> <given-names>G</given-names></name><name><surname>Scapulatempo-Neto</surname> <given-names>C</given-names></name><name><surname>Schein</surname> <given-names>JE</given-names></name><name><surname>Schuckman</surname> <given-names>AK</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Shelton</surname> <given-names>C</given-names></name><name><surname>Shelton</surname> <given-names>T</given-names></name><name><surname>Shukla</surname> <given-names>SA</given-names></name><name><surname>Simko</surname> <given-names>J</given-names></name><name><surname>Singh</surname> <given-names>P</given-names></name><name><surname>Sipahimalani</surname> <given-names>P</given-names></name><name><surname>Smith</surname> <given-names>ND</given-names></name><name><surname>Sofia</surname> <given-names>HJ</given-names></name><name><surname>Sorcini</surname> <given-names>A</given-names></name><name><surname>Stanton</surname> <given-names>ML</given-names></name><name><surname>Steinberg</surname> <given-names>GD</given-names></name><name><surname>Stoehr</surname> <given-names>R</given-names></name><name><surname>Su</surname> <given-names>X</given-names></name><name><surname>Sullivan</surname> <given-names>T</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Tam</surname> <given-names>A</given-names></name><name><surname>Tarnuzzer</surname> <given-names>R</given-names></name><name><surname>Tarvin</surname> <given-names>K</given-names></name><name><surname>Taubert</surname> <given-names>H</given-names></name><name><surname>Thiessen</surname> <given-names>N</given-names></name><name><surname>Thorne</surname> <given-names>L</given-names></name><name><surname>Tse</surname> <given-names>K</given-names></name><name><surname>Tucker</surname> <given-names>K</given-names></name><name><surname>Van Den Berg</surname> <given-names>DJ</given-names></name><name><surname>van Kessel</surname> <given-names>KE</given-names></name><name><surname>Wach</surname> <given-names>S</given-names></name><name><surname>Wan</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Weisenberger</surname> <given-names>DJ</given-names></name><name><surname>Wise</surname> <given-names>L</given-names></name><name><surname>Wong</surname> <given-names>T</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Zach</surname> <given-names>LA</given-names></name><name><surname>Zenklusen</surname> <given-names>JC</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zmuda</surname> <given-names>E</given-names></name><name><surname>Zwarthoff</surname> <given-names>EC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer</article-title><source>Cell</source><volume>171</volume><fpage>e525</fpage><lpage>e556</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.007</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roos</surname> <given-names>WP</given-names></name><name><surname>Thomas</surname> <given-names>AD</given-names></name><name><surname>Kaina</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>DNA damage and the balance between survival and death in Cancer biology</article-title><source>Nature Reviews Cancer</source><volume>16</volume><fpage>20</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/nrc.2015.2</pub-id><pub-id pub-id-type="pmid">26678314</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sale</surname> <given-names>JE</given-names></name><name><surname>Calandrini</surname> <given-names>DM</given-names></name><name><surname>Takata</surname> <given-names>M</given-names></name><name><surname>Takeda</surname> <given-names>S</given-names></name><name><surname>Neuberger</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Ablation of XRCC2/3 transforms immunoglobulin V gene conversion into somatic hypermutation</article-title><source>Nature</source><volume>412</volume><fpage>921</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1038/35091100</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaaper</surname> <given-names>RM</given-names></name><name><surname>Dunn</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Spectra of spontaneous mutations in Escherichia coli strains defective in mismatch correction: the nature of in vivo DNA replication errors</article-title><source>PNAS</source><volume>84</volume><fpage>6220</fpage><lpage>6224</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.17.6220</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Xie</surname> <given-names>D</given-names></name><name><surname>Xiao</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Jiang</surname> <given-names>K</given-names></name><name><surname>Liao</surname> <given-names>L</given-names></name><name><surname>Lee</surname> <given-names>J-D</given-names></name><name><surname>Yang</surname> <given-names>Q</given-names></name><name><surname>Yang</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent</article-title><source>Cancer Research</source><volume>78</volume><fpage>2475</fpage><lpage>2489</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3091</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoma</surname> <given-names>CR</given-names></name><name><surname>Toso</surname> <given-names>A</given-names></name><name><surname>Gutbrodt</surname> <given-names>KL</given-names></name><name><surname>Reggi</surname> <given-names>SP</given-names></name><name><surname>Frew</surname> <given-names>IJ</given-names></name><name><surname>Schraml</surname> <given-names>P</given-names></name><name><surname>Hergovich</surname> <given-names>A</given-names></name><name><surname>Moch</surname> <given-names>H</given-names></name><name><surname>Meraldi</surname> <given-names>P</given-names></name><name><surname>Krek</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>VHL loss causes spindle misorientation and chromosome instability</article-title><source>Nature Cell Biology</source><volume>11</volume><fpage>994</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1038/ncb1912</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomecki</surname> <given-names>R</given-names></name><name><surname>Drazkowska</surname> <given-names>K</given-names></name><name><surname>Dziembowski</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mechanisms of RNA Degradation by the Eukaryotic Exosome</article-title><source>ChemBioChem</source><volume>11</volume><fpage>938</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1002/cbic.201000025</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tubbs</surname> <given-names>A</given-names></name><name><surname>Nussenzweig</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endogenous DNA Damage as a Source of Genomic Instability in Cancer</article-title><source>Cell</source><volume>168</volume><fpage>644</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.01.002</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tutt</surname> <given-names>A</given-names></name><name><surname>Robson</surname> <given-names>M</given-names></name><name><surname>Garber</surname> <given-names>JE</given-names></name><name><surname>Domchek</surname> <given-names>SM</given-names></name><name><surname>Audeh</surname> <given-names>MW</given-names></name><name><surname>Weitzel</surname> <given-names>JN</given-names></name><name><surname>Friedlander</surname> <given-names>M</given-names></name><name><surname>Arun</surname> <given-names>B</given-names></name><name><surname>Loman</surname> <given-names>N</given-names></name><name><surname>Schmutzler</surname> <given-names>RK</given-names></name><name><surname>Wardley</surname> <given-names>A</given-names></name><name><surname>Mitchell</surname> <given-names>G</given-names></name><name><surname>Earl</surname> <given-names>H</given-names></name><name><surname>Wickens</surname> <given-names>M</given-names></name><name><surname>Carmichael</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial</article-title><source>The Lancet</source><volume>376</volume><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60892-6</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Sjöstedt</surname> <given-names>E</given-names></name><name><surname>Fagerberg</surname> <given-names>L</given-names></name><name><surname>Bidkhori</surname> <given-names>G</given-names></name><name><surname>Benfeitas</surname> <given-names>R</given-names></name><name><surname>Arif</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Edfors</surname> <given-names>F</given-names></name><name><surname>Sanli</surname> <given-names>K</given-names></name><name><surname>von Feilitzen</surname> <given-names>K</given-names></name><name><surname>Oksvold</surname> <given-names>P</given-names></name><name><surname>Lundberg</surname> <given-names>E</given-names></name><name><surname>Hober</surname> <given-names>S</given-names></name><name><surname>Nilsson</surname> <given-names>P</given-names></name><name><surname>Mattsson</surname> <given-names>J</given-names></name><name><surname>Schwenk</surname> <given-names>JM</given-names></name><name><surname>Brunnström</surname> <given-names>H</given-names></name><name><surname>Glimelius</surname> <given-names>B</given-names></name><name><surname>Sjöblom</surname> <given-names>T</given-names></name><name><surname>Edqvist</surname> <given-names>P-H</given-names></name><name><surname>Djureinovic</surname> <given-names>D</given-names></name><name><surname>Micke</surname> <given-names>P</given-names></name><name><surname>Lindskog</surname> <given-names>C</given-names></name><name><surname>Mardinoglu</surname> <given-names>A</given-names></name><name><surname>Ponten</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A pathology atlas of the human cancer transcriptome</article-title><source>Science</source><volume>357</volume><elocation-id>eaan2507</elocation-id><pub-id pub-id-type="doi">10.1126/science.aan2507</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulmke</surname> <given-names>PA</given-names></name><name><surname>Xie</surname> <given-names>Y</given-names></name><name><surname>Sokpor</surname> <given-names>G</given-names></name><name><surname>Pham</surname> <given-names>L</given-names></name><name><surname>Shomroni</surname> <given-names>O</given-names></name><name><surname>Berulava</surname> <given-names>T</given-names></name><name><surname>Rosenbusch</surname> <given-names>J</given-names></name><name><surname>Basu</surname> <given-names>U</given-names></name><name><surname>Fischer</surname> <given-names>A</given-names></name><name><surname>Nguyen</surname> <given-names>HP</given-names></name><name><surname>Staiger</surname> <given-names>JF</given-names></name><name><surname>Tuoc</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Post-transcriptional regulation by the exosome complex is required for cell survival and forebrain development via repression of P53 signaling</article-title><source>Development</source><volume>148</volume><elocation-id>dev188276</elocation-id><pub-id pub-id-type="doi">10.1242/dev.188276</pub-id><pub-id pub-id-type="pmid">33462115</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Sun</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Yu</surname> <given-names>S-C</given-names></name><name><surname>Yang</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>NADP modulates RNA m6A methylation and adipogenesis via enhancing FTO activity</article-title><source>Nature Chemical Biology</source><volume>16</volume><fpage>1394</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-0601-2</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasmuth</surname> <given-names>EV</given-names></name><name><surname>Januszyk</surname> <given-names>K</given-names></name><name><surname>Lima</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structure of an Rrp6–RNA exosome complex bound to poly(A) RNA</article-title><source>Nature</source><volume>511</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/nature13406</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Collisson</surname> <given-names>EA</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Shaw</surname> <given-names>KRM</given-names></name><name><surname>Ozenberger</surname> <given-names>BA</given-names></name><name><surname>Ellrott</surname> <given-names>K</given-names></name><name><surname>Shmulevich</surname> <given-names>I</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Stuart</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1113</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1038/ng.2764</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Q</given-names></name><name><surname>Deng</surname> <given-names>X</given-names></name><name><surname>Lu</surname> <given-names>B</given-names></name><name><surname>Cameron</surname> <given-names>M</given-names></name><name><surname>Fearns</surname> <given-names>C</given-names></name><name><surname>Patricelli</surname> <given-names>MP</given-names></name><name><surname>Yates</surname> <given-names>JR</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name><name><surname>Lee</surname> <given-names>J-D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein</article-title><source>Cancer Cell</source><volume>18</volume><fpage>258</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.08.008</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Kwok-Shing Ng</surname> <given-names>P</given-names></name><name><surname>Kucherlapati</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Tsang</surname> <given-names>YH</given-names></name><name><surname>de Velasco</surname> <given-names>G</given-names></name><name><surname>Jeong</surname> <given-names>KJ</given-names></name><name><surname>Akbani</surname> <given-names>R</given-names></name><name><surname>Hadjipanayis</surname> <given-names>A</given-names></name><name><surname>Pantazi</surname> <given-names>A</given-names></name><name><surname>Bristow</surname> <given-names>CA</given-names></name><name><surname>Lee</surname> <given-names>E</given-names></name><name><surname>Mahadeshwar</surname> <given-names>HS</given-names></name><name><surname>Tang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Seth</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Ren</surname> <given-names>X</given-names></name><name><surname>Song</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Seidman</surname> <given-names>J</given-names></name><name><surname>Luquette</surname> <given-names>LJ</given-names></name><name><surname>Xi</surname> <given-names>R</given-names></name><name><surname>Chin</surname> <given-names>L</given-names></name><name><surname>Protopopov</surname> <given-names>A</given-names></name><name><surname>Westbrook</surname> <given-names>TF</given-names></name><name><surname>Shelley</surname> <given-names>CS</given-names></name><name><surname>Choueiri</surname> <given-names>TK</given-names></name><name><surname>Ittmann</surname> <given-names>M</given-names></name><name><surname>Van Waes</surname> <given-names>C</given-names></name><name><surname>Weinstein</surname> <given-names>JN</given-names></name><name><surname>Liang</surname> <given-names>H</given-names></name><name><surname>Henske</surname> <given-names>EP</given-names></name><name><surname>Godwin</surname> <given-names>AK</given-names></name><name><surname>Park</surname> <given-names>PJ</given-names></name><name><surname>Kucherlapati</surname> <given-names>R</given-names></name><name><surname>Scott</surname> <given-names>KL</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Kwiatkowski</surname> <given-names>DJ</given-names></name><name><surname>Creighton</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations</article-title><source>Cancer Cell</source><volume>31</volume><fpage>820</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.04.013</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>T</given-names></name><name><surname>Simon</surname> <given-names>J</given-names></name><name><surname>Takada</surname> <given-names>M</given-names></name><name><surname>Saito</surname> <given-names>R</given-names></name><name><surname>Fan</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>X-D</given-names></name><name><surname>Jonasch</surname> <given-names>E</given-names></name><name><surname>Xie</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Yao</surname> <given-names>X</given-names></name><name><surname>Teh</surname> <given-names>BT</given-names></name><name><surname>Tan</surname> <given-names>P</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Lawrence</surname> <given-names>C</given-names></name><name><surname>Fan</surname> <given-names>J</given-names></name><name><surname>Geng</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Hu</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Liao</surname> <given-names>C</given-names></name><name><surname>Hong</surname> <given-names>K</given-names></name><name><surname>Zurlo</surname> <given-names>G</given-names></name><name><surname>Parker</surname> <given-names>JS</given-names></name><name><surname>Auman</surname> <given-names>JT</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Rathmell</surname> <given-names>WK</given-names></name><name><surname>Kim</surname> <given-names>WY</given-names></name><name><surname>Kirschner</surname> <given-names>MW</given-names></name><name><surname>Kaelin</surname> <given-names>WG</given-names></name><name><surname>Baldwin</surname> <given-names>AS</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma</article-title><source>Science</source><volume>361</volume><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1126/science.aap8411</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>S-L</given-names></name><name><surname>Zhou</surname> <given-names>Z-J</given-names></name><name><surname>Hu</surname> <given-names>Z-Q</given-names></name><name><surname>Song</surname> <given-names>C-L</given-names></name><name><surname>Luo</surname> <given-names>Y-J</given-names></name><name><surname>Luo</surname> <given-names>C-B</given-names></name><name><surname>Xin</surname> <given-names>H-Y</given-names></name><name><surname>Yang</surname> <given-names>X-R</given-names></name><name><surname>Shi</surname> <given-names>Y-H</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Huang</surname> <given-names>X-W</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Fan</surname> <given-names>J</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence</article-title><source>Journal of Hepatology</source><volume>71</volume><fpage>1152</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.07.014</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.69454.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution>Shengjing Hospital of China Medical University</institution><country>China</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Wu</surname><given-names>Longtao</given-names> </name><role>Reviewer</role><aff><institution>University of Chicago</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.04.18.440347">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.04.18.440347v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>In this study, a novel molecule, EXOSC1 was proposed to be associated with DNA damage, and thus could serve as potential biomarker predicting efficacy of therapy in kidney cancer. The studies were rigorously designed and executed to illustrate the main points.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Exosome component 1 cleaves single-stranded DNA and sensitizes kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Mone Zaidi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Longtao Wu (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The amount of work was sufficient to justify the conclusion. However, validation through basic experiment and clinical data analysis still requires further improvement.</p><p>2) Data presentation in the figures could be adjusted more reasonable, and several questions regarding the figures remain to be explained for enriching the content and improving this work better.</p><p>3) Some points in the manuscript were not in accordance with the figures, please check and make corresponding adjustments.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. In line 147-148: 'KIRC displayed higher frequencies of C&gt;A/G&gt;T, A&gt;T/T&gt;A, and A&gt;C/T&gt;G mutations', as is manifested in Figure 1I, most frequently mutated substitutions are C&gt;T/G&gt;A, which is not in accordance with the description.</p><p>2. In figure 6, the photographs on tumor mass from PDX implanted with control and EXOSC1-OE cells need to be exhibited along with the plot to enrich the in vivo experiment data.</p><p>3. As is discussed in this manuscript, EXOSC1 could potentially function as one biomarker facilitating selection of target patients who will benefit from DNA repair inhibitor therapy, supplement of retrospective clinical data analysis which manifest that KIRC patients with high level of EXOSC1 benefit more from DNA repair inhibitor therapy would be better.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>There are some concerns on this work:</p><p>1. Figure 1E GAPDH is C&gt;A/G&gt;T mutation, yet CRB3 in the content was A&gt;T/T&gt;A, the authors should be consistent.</p><p>2. Figure 1F, have authors tried to do pathway analyses with top candidate genes to check if there are any significant pathways are associated with KIRC?</p><p>3. Figure 1I, it will have helpful to figure out among the patient mutations, how many are function related? Are there any mutations contribute to KIRC progression?</p><p>4. Please check supplemental table S3 to make sure the number of the genes are consistent with the text. There are only 30plus genes in the table, and no RAB5IF listed.</p><p>5. Figure 2E, please have a better picture, change the background color may help.</p><p>6. Figure 3, have the authors ever test the DNA cleavage activity with all the exosome components, or at least the combination of 1,7 and 8 as the authors mentioned 7 and 8 could inhibit 1 in the discussion.</p><p>7. Figure 4, to be relevant to KIRC, hot spot of VHL mutation should be used in the assay to support the author's main point of the paper.</p><p>8. Figure 4H, please be clear on groups in the figure legend, what 2,3,4,5 group mean?</p><p>9. Figure 5J, it will be nice to have survival or tumor burden data for this experiment. It will be very supportive for the manuscript.</p><p>10. Figure 6, as the authors indicated in Figure 1, four other tumor types also have high mutations, it will be interesting to examine whether DFS or OS will be different based on EXOC1 expression.</p><p>11. It will be ideal that the authors can test whether EXOSC1 has paracrine effect or not.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.69454.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The amount of work was sufficient to justify the conclusion. However, validation through basic experiment and clinical data analysis still requires further improvement.</p><p>2) Data presentation in the figures could be adjusted more reasonable, and several questions regarding the figures remain to be explained for enriching the content and improving this work better.</p><p>3) Some points in the manuscript were not in accordance with the figures, please check and make corresponding adjustments.</p><p>Reviewer #1 (Recommendations for the authors):</p><p>1. In line 147-148: 'KIRC displayed higher frequencies of C&gt;A/G&gt;T, A&gt;T/T&gt;A, and A&gt;C/T&gt;G mutations', as is manifested in Figure 1I, most frequently mutated substitutions are C&gt;T/G&gt;A, which is not in accordance with the description.</p></disp-quote><p>We are so sorry that this part was not clear in the first version. Mutation frequencies analyses indicated that the most frequently mutated substitutions in the five major cancers were C&gt;T/G&gt;A, but KIRC displayed higher frequencies of C&gt;A/G&gt;T, A&gt;T/T&gt;A, and A&gt;C/T&gt;G mutations than the other four cancers did (Figure 1I). As suggested, more information was included in the line 153-156 of the revised version.</p><disp-quote content-type="editor-comment"><p>2. In figure 6, the photographs on tumor mass from PDX implanted with control and EXOSC1-OE cells need to be exhibited along with the plot to enrich the in vivo experiment data.</p></disp-quote><p>As suggested, we did try to present photographs on tumors from PDX. As shown in Figure 6, the mice were executed on the different days. To take a photograph containing all the tumors from different groups, control and EXOSC1-OE tumors without Niraparib treatment were stored at -80°C. However the freeze-thaw cycle resulted in a notable shrinkage of these tumors, which might lead to misunderstanding. It is really embarrassing!</p><disp-quote content-type="editor-comment"><p>3. As is discussed in this manuscript, EXOSC1 could potentially function as one biomarker facilitating selection of target patients who will benefit from DNA repair inhibitor therapy, supplement of retrospective clinical data analysis which manifest that KIRC patients with high level of EXOSC1 benefit more from DNA repair inhibitor therapy would be better.</p></disp-quote><p>As suggested, we tried to retrospectively analyze the clinical data of KIRC patients treated with DNA repair inhibitor(s) to evaluate the role of EXOSC1. Due to the clinical potential of DNA repair inhibitor(s), multi clinical trials of the DNA repair inhibitor(s) such as Niraparib (NCT number: NCT03207347) in KIRC were initiated. Unfortunately, we found that all of these clinical trials are not completed or the clinical trial data are not released. We are so sorry about this. And we would be glad to respond to any further comments that you may have.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>There are some concerns on this work:</p><p>1. Figure 1E GAPDH is C&gt;A/G&gt;T mutation, yet CRB3 in the content was A&gt;T/T&gt;A, the authors should be consistent.</p></disp-quote><p>As suggested, the correlation between CRB3 expression and C&gt;A/G&gt;T mutation was shown in the Figure 1E of the revised version.</p><disp-quote content-type="editor-comment"><p>2. Figure 1F, have authors tried to do pathway analyses with top candidate genes to check if there are any significant pathways are associated with KIRC?</p></disp-quote><p>Yes, we have performed pathway analyses. GO enrichment analyses indicated that, generally, these top candidate genes showed the more significant enrichment in “mitochondrial gene expression” and “organophosphate biosynthetic process” (line 130-133, Figure 1—figure supplement 1A).</p><disp-quote content-type="editor-comment"><p>3. Figure 1I, it will have helpful to figure out among the patient mutations, how many are function related? Are there any mutations contribute to KIRC progression?</p></disp-quote><p>As suggested, the information of function related mutations in KIRC was included in the revised version (line 156-160, Figure 1—figure supplement 1B).</p><disp-quote content-type="editor-comment"><p>4. Please check supplemental table S3 to make sure the number of the genes are consistent with the text. There are only 30plus genes in the table, and no RAB5IF listed.</p></disp-quote><p>We are so sorry for this terrible typo. “66” should be “36”. And C20ORF24 in Supplemental Table S3 is the previous gene name (aliase) of RAB5IF gene (Gene ID: 55969). It is really embarrassing. The corrected information was included in the line 174 and Supplemental Table S3 of the revised version.</p><disp-quote content-type="editor-comment"><p>5. Figure 2E, please have a better picture, change the background color may help.</p></disp-quote><p>As suggested, the background color of Figure 2E was changed in the revised version.</p><disp-quote content-type="editor-comment"><p>6. Figure 3, have the authors ever test the DNA cleavage activity with all the exosome components, or at least the combination of 1,7 and 8 as the authors mentioned 7 and 8 could inhibit 1 in the discussion.</p></disp-quote><p>As suggested, the DNA cleavage activity with all the exosome components (EXOSC1–9) was test. And all the exosome components (exosome complex) displayed not detect DNA cleavage activity (line 240-241, Figure 3—figure supplement 1C).</p><disp-quote content-type="editor-comment"><p>7. Figure 4, to be relevant to KIRC, hot spot of VHL mutation should be used in the assay to support the author's main point of the paper.</p></disp-quote><p>As suggested, a 20 nt ssDNA containing hot spot of VHL mutation (186-205) was used in the assay. And EXOSC1 cleaved the ssDNA containing hot spot of VHL mutation (line 262-263, Figure 4—figure supplement 1E).</p><disp-quote content-type="editor-comment"><p>8. Figure 4H, please be clear on groups in the figure legend, what 2,3,4,5 group mean?</p></disp-quote><p>We are so sorry that this part was not clear in the first version. 2, 3, 4 and 5 are the group numbers. For example, 4: the KIRC patients were grouped into 4 groups and the expression difference of EXOSC1 between the high and low mutation groups was analyzed by student’s <italic>t</italic>-tests. As suggested, more information was included in the figure legend of the revised version.</p><disp-quote content-type="editor-comment"><p>9. Figure 5J, it will be nice to have survival or tumor burden data for this experiment. It will be very supportive for the manuscript.</p></disp-quote><p>We are so sorry that this part was not clear in the first version. We supposed that Figure 6G and 6I could be used to evaluate the survival or tumor burden data of Figure 5J. And we would be glad to respond to any further comments that you may have.</p><disp-quote content-type="editor-comment"><p>10. Figure 6, as the authors indicated in Figure 1, four other tumor types also have high mutations, it will be interesting to examine whether DFS or OS will be different based on EXOC1 expression.</p></disp-quote><p>As suggested, we examined whether OS was different based on EXOC1 expression. Median separation KM analyses indicated that OS was not significantly different based on EXOC1 expression (BRCA <italic>p</italic> = 0.61, BLCA <italic>p</italic> = 0.20, GBM <italic>p</italic> = 0.72 and AML <italic>p</italic> = 0.17) (line 356-360, Figure 6—figure supplement 1D).</p><disp-quote content-type="editor-comment"><p>11. It will be ideal that the authors can test whether EXOSC1 has paracrine effect or not.</p></disp-quote><p>As suggested, overexpression of EXOSC1 in MEF increased the production of interferon b (IFNb). However, overexpression of EXOSC1 showed little impact on the production of IFNb in cancer cells, which might be because that cGAS/sting pathway is frequently inactivated in the most cancer cells.</p></body></sub-article></article>